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ABSTRACT 
Peptidomimetics can mimic hierarchical structures of peptides and proteins. Thus, they are 
extensively studied for therapeutic applications. To break the limitation of backbones and frameworks 
and expand the peptidomimetics family, a new class of peptidomimetics - “γ-AApeptides” was 
developed. Design of γ-AApeptides is based on the chiral peptide nucleic acids (PNAs) backbone. 
The World Health Organization estimates that one -third of all deaths in the world are on 
account of infectious diseases. AMPs are important because of their high activity against broad 
spectrum microbes, less susceptible to grow resistance and selectivity in binding to bacterial cells over 
human cells. γ-AApeptides as a new class of peptidomimetics have increased stability and enhanced 
chemical diversity. We have developed polymyxin mimic cyclic peptides, small linear molecules and 
hydantoin derivatives as potent antibiotic agents with γ-AApeptides. They have good bioactivity and 
selectivity. 
Combinatorial library is key technology for accelerating the discovery of novel therapeutic 
agents. One-bead-two-compound γ-AApeptides-based library was developed and screened against 
SMYD2 protein which is essential for tumor growing.
1 
 
 
 
 
 
 
CHAPTER 1: INTRODUCTION 
1.1 Antibiotic resistance overview 
As a major cause of morbidity and mortality, infectious diseases have threatened human health 
throughout the mankind history. The World Health Organization estimates that one -third of all deaths 
in the world are on account of infectious diseases1. Pneumonia and influenza are the fourth-leading 
causes of death in older adults, and bacteremia is the ninth-leading cause of death2. Discovery of 
penicillin in 1928 represented an start of “antibiotic” era2. The major death cause change from infectious 
diseases to the chronic diseases.   
However, bigger problem has been resulted due to misuse and overuse antibiotics. Drug-resistant 
strains initially showed up in places where most antibiotics were being used very soon after the 
introduction of penicillin 3. For example, sulfonamide-resistant Streptoccoccus pyogenes appeared in 
military hospitals in the 1930s4, and penicillin-resistant Staphylococcus aureus emerged in civilian 
hospitals in the 1940s5. The frequency of resistance promoted in many different bacteria due to the 
increasing antimicrobial use. In the late 1950s to early 1960s, multiple drugs resistance (MDR) was 
first detected among Escherichia coli, Shigella and Salmonella6-7. Treatment of MDR infections are 
more precarious, costly and sometimes unsuccessful because all available drugs have failed. For 
example, E. faecium have plagued immunocompromised individuals in hospitals in the United States 
and other places for more than a decade as a MDR strain8. Methicillin-resistant Staphylococcus aureus 
(MRSA) has been the most frequently isolated resistant pathogens in the older population and was one 
of the earlier resistant pathogens described as a major clinical problem in long-term care facilities9. 
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Unfortunately, resistance to methicillin is not the only issue; MRSA is generally resistant to all 
quinolones and cephalosporins as well.10 Although vancomycin has become the main therapy for MRSA, 
recent studies point out the worrying evidence that Staphylococcus aureus with resistance to 
vancomycin already emerged. Among the Gram-negative bacteria, hospital infections caused by P. 
aeruginosa and A. baumanii can result in death because of their resistance to most antibiotics11. The 
frequency of drug resistance emergence has extended the problem beyond the hospital and can be traced 
to the community. 
What causes drug resistance? Microbes have been existing since primitive times. Their evolution 
to adapt themselves to innumerable ecological microcosms already took over a period of 3.5 billion 
years. Due to their rapid rate of multiplication and genetic makeup ability, microbes can survive from 
and adapt to environment changes by incorporating all the beneficial mutations to evolve. The antibiotic 
selects the resistant organisms by inhibiting susceptible ones, and the determinant resistance genes are 
selected12. Under continued antimicrobial selection, resistance genes can be spread and propagated. 
Furthermore, the genes for resistance traits can be transferred among different bacteria groups by means 
of mobile genetic elements such as plasmids, transposons, naked DNA or bacteriophages13. Resistance 
mechanisms are varied.  
Resistance mechanisms vary. One type of mechanisms is directed at the antibiotic itself. For example, 
it was discovered that an enzyme produced by bacteria can destroy the β-lactam ring of antibiotics14. 
Targeting drug transportation and altering intracellular target of the drug are other two types of 
mechanisms15. It is also indicated that losing drug resistance is slow, even in the absence of the selecting 
antibiotic. 
One of the approaches to manage and prevent drug resistance is continuing, steady development 
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of new antibiotics. From what we have learned, shorter-course therapies with highly active antibiotics 
will reduce multidrug resistance. The development of new antibiotics with different mechanisms—
either attack new targets or circumvent resistance mechanisms—is essential.  
1.2 Antimicrobial peptides (AMPs) overview 
In 1922, the first bacteriolytic enzyme was found from nasal mucous by Alexander Fleming. Later in 
1928, Fleming discovered penicillin extracted from Penicillium notatum.14 Subsequently, Stephens and 
Marshall isolated antimicrobial peptides (AMPs) from hemolymph of wax moth larvae in 1962.16 AMPs are 
defined as peptides produced by immune system to protect the body from bacteria, fungi and viruses and 
can be found in all forms of life in variable sequences. AMPs can be classified into different classes due to 
the secondary structure in solution: α-helical peptides, β-sheet peptides, extended peptides and loop 
peptides.17 The most common characteristics of AMPs are positive charge and hydrophobic residues. Based 
on their different action modes, AMPs have been subdivided into two classes: membrane permeabilization 
and intracellular targeting.18 Membrane permeabilization is the most common mode of action. The cationic 
groups electrostatically attract and bind to bacteria membrane with negative charge and hydrophobic groups 
interact with lipid bilayers to burrow and penetrate into the bacterial cell.19-20 Different types of model 
mechanisms have been proposed: barrel stave model, carpet model and toroidal model.21 Intracellular 
targeting includes altering the cellular pathways of the bacteria and inhibiting the DNA, RNA and folic acid 
synthesis.22 
AMPs are important because of their high activity against broad spectrum microbes, less susceptible 
to grow resistance and selectivity in binding to bacterial cells over human cells.23 However, AMPs have to 
overcome limitations such as proteolytic degradation, rapid metabolism, poor pharmacodynamic and 
pharmacokinetic properties.24 To increase their potential as drug, synthesis of peptidomimetics is needed to 
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mimic the action mode and decrease the limitations.25 
1.3 γ-AA peptide overview 
In the past decade, peptidomimetics offer important applications and exciting approaches in 
chemical biology26. Due to their unnatural backbones, peptidomimetics could overcome obstacles of 
conventional peptides, including susceptibility to enzymatic hydrolysis, low bioavailability, and limited 
chemodiversity27. Peptidomimetics can mimic hierarchical structures of peptides and proteins. Thus, 
they are extensively studied for therapeutic applications, such as peptoids28, β-peptides29, α/β-peptides30, 
oligoureas31, azapeptides32, and so forth.  
To break the limitation of backbones and frameworks and expand the peptidomimetics family, a 
new class of peptidomimetics - “γ-AApeptides” was developed. Design of γ-AApeptides is based on 
the chiral peptide nucleic acids (PNAs) backbone33. They are termed γ-AApeptides, as they are 
oligomers of γ-substituted-N-acylated-N-aminoethyl amino acids34. As peptidomimetics, γ-AApeptides 
also possess resistance to proteolytic degradation and enhanced chemodiversity. In addition, one of the 
most attractive features of γ-AApeptides is that the secondary amines on the backbone can react with 
innumerable agents besides carboxylic acids to introduce half of their side chains. 
We have developed several intriguing structures and applications of γ-AApeptides. For example, 
they could permeate cell membranes and specifically bind to HIV RNA by mimicking the Tat peptide35. 
We also rationally designed some γ-AApeptides for a range of biological applications. By mimicking 
host-defense peptides (HDPs), γ-AApeptides displayed potent and broad-spectrum activity against a 
panel of drug resistant bacterial pathogens36. Meanwhile, γ-AApeptides are also capable for 
combinatorial library screening because of their stability against proteolysis and their chemodiversity37. 
Through combinatorial selection, certain γ-AApeptides can disrupt Aβ peptide aggregation, and few γ-
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AApeptides can bind to the DNA-binding domain of STAT3 and inhibit STAT3/DNA interactions38.  
Our studies suggest that γ-AApeptides can mimic primary and secondary structures of bioactive 
peptides. In addition, they are promising candidates for combinatorial development for the identification 
of molecular probes and potential drug leads. With further development of both structures and functions, 
γ-AApeptides may play an important role in biomedical sciences as a new class of peptidomimetics. 
1.4 Combinatorial library overview 
In the 1990s, combinatorial chemistry has drawn substantial attention from the pharmaceutical 
industry due to its ability of greatly facilitating drug discovery process39. 
Combinatorial chemistry is considered as one of the most important advances in medicinal chemistry. 
Moreover, it is also an enormously powerful tool in basic research. 
Combinatorial library methods have various applications in many fields, such as peptides,40-41 
oligonucleotides,42-43 proteins,44 synthetic oligomers,45 small molecules,46 and oligosaccharides.47 
Three main steps are involved in all combinatorial library methods: (i) prepare the library, (ii) 
screen the library, and (iii) determine the chemical structures of active compounds. In general, 
combinatorial libraries are prepared on a solid phase.48-49 Manageably large collection of amino acids 
and well development of solid-phase coupling make solid-phase peptide synthesis become the 
combinatorial library approach. A beaded polymer using as solid phase needs to meet certain criteria 
according to the synthetic and screening approaches: size uniformity, substitution homogeneity, 
resistance to clusters formation and ability to swell in both organic and aqueous solvents. TentaGel was 
discovered as the choice of solid support for combinatorial library synthesis due to its uniformity in size 
and nonstickiness.50 In addition, functionalizable groups of TentaGel are located at the end of 
polyoxyethylene chains, which is essential for compound display on the resin bead surface for binding 
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assay.. 
The one-bead-one-compound concept was first brought forward by Lam et al.51. This library was 
prepared using a “split synthesis” approach (Figure 2), which was described recognized by Furka et al. 
in 1988. The synthesis of this library begins with x portions of the resin beads coupling with x different 
building blocks. Each portion is then divided into y pieces and distributed into y reaction vessels to react 
with y different reagents. The process can be repeated as many times as required and will produce a 
library of x × y × … = N compounds on N resin beads.  
Cleavable linkers fulfilling several main requirements are needed for screening and structures 
determining: (i) ability to stay stable during all the reactions of library synthesis, (ii) end products are 
readily cleaved from the resin beads, (iii) library compounds will not degrade in cleavage process, (iv) 
user friendly and provide the released compounds ready for screening.39 There are two screening 
approaches for on-bead screening: target binding to the ligand or other functional properties of the 
ligand. The binding of target to bead-bound ligand can be detected either by direct visualization such 
as color target, or indirectly by using a reporter group such as an enzyme or a fluorescent probe attached 
to a target.39 The most expedient method for compound detachment is exposing resin beads to gaseous 
reagents, such as ammonia, cyanogen bromide and hydrogen fluride. 
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Figure 1.1 Scheme of the “split synthesis” method.52 (Adapted with permission from Nature 1991, 354, 
82. Copyright 1997 Springer Nature.) 
 
Mass spectrometry is a very sensitive analytical tool for library characterization.53 Mass 
spectrometry can identify complement amino acid sequencing,54 unnatural amino acids sequences55 and 
all types of impurities from the synthesis or cleavage process. In addition, mass spectrometric analysis 
of several hundred samples can be performed automatically.56  
The molecular biology revolution enables researchers to clone and express biological receptors, 
enzymes, and proteins routinely. Many new drug targets for various diseases have now been identified. 
Since the initial publication of the one-bead-one-compound combinatorial library method, there have 
been numerous applications to various biological targets such as monoclonal antibodies,57-59 
streptavidin/avidin,60-61 protein kinase,62-63 protease,64 and anticancer agent.65 The development of 
combinatorial chemistry is timely and undoubtedly will contribute to discovering new drugs that can 
benefit the whole mankind. Since peptide-protein, protein-nucleic acid, and protein- protein interactions 
represent the major molecular interactions and signal in living cells and organisms, peptide library 
methods will keep playing an important role in identifying drug leads and developing drug candidates.  
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CHAPTER 2: MEMBRANE-ACTIVE HYDANTOIN DERIVATIVES AS ANTIBIOTIC 
AGENTS 
 
Note to Reader 
Contents in this chapter have been previously published in Journal of Medicinal Chemistry, 2017, 
60 (20), pp 8456–8465, and have been reproduced with the permission of the American Chemical 
Society (ACS). 
 
2.1 Introduction 
Infection caused by drug-resistant bacteria has become one of the greatest threats to public health 
in the 21st century66. Exploration for alternative therapeutic strategies is in a huge demand. One 
promising approach is to reinvestigate known antibiotics and design their derivatives, in the hope of 
identifying novel antibiotic agents that combat antibiotic resistance. Hydantoins, the derivatives of 2,4-
imidazolidinedione, have been developed for antibacterial applications for long time. 67-73 The 
mechanism of action for hydantoin derivatives is complex and not well understood, possibly due to 
their damage to bacterial DNA,74-76 as well as binding to bacterial ribosomes to inhibit synthesis of 
critical bacterial enzymes.77 To date, one hydantoin derivative, nitrofurantoin, was approved to treat 
urinary tract infections.78-84 As an old antibiotic, it recently attracted considerable interest due to their 
low probability of bacterial resistance compared to other conventional antibiotics such as 
fluoroquinolones,85-86 possibly owing to their mixed mechanisms of action.87-88 However, hydantoin 
derivatives including nitrofurantoin generally exhibit only moderate antibacterial activity, which may 
limit their further application in combating emergent antibiotic resistance.89-91 For instance, 
nitrofurantoin (Figure 2.1) show a MIC of 12.5 µg/mL for MRSA, and it is even not active towards P. 
aeruginosa up to 100 µg/mL.89-91 
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Figure 2.1 Structure of nitrofurantoin. 
 
Another alternative strategy to combat antibiotic resistance is to develop cationic host-defense 
peptides (HDPs) as potential antibiotic agents. Containing hydrophobic and cationic groups, HDPs 92-
93 and related peptidomimetics such as β-peptides94-96, oligoureas 97, peptoids98-99, AApeptides100-101, etc., 
are able to selectively interaction with negatively charged bacterial membranes, leading to membrane 
damage and cell death. Cationic charges are critical for association of these molecules with bacterial 
membranes, while hydrophobic groups are of importance for membrane penetration and disruption. 
HDPs and their derivatives are believed to minimize the potential of bacterial resistance development, 
as the membrane interaction and disruption is rather biophysical and lack specific membrane targets. It 
should be noted that many HDPs could also permeate bacterial membranes and act on bacteria 
intracellular targets92, 102-104. Indeed, the mixed antibacterial mechanisms are expected to further 
strengthen their ability to combat bacterial resistance. Despite considerable enthusiasm, HDPs and 
oligomeric peptidomimetics encounter obstacles for antibiotic development, including moderate 
activity and systematic toxicity105-106. In addition, their large molecular weights (normally >1000 Da) 
and structural complexity lead to tedious synthetic process and costly production, hampering the 
therapeutic development of HDPs.  
Inspired by the structures of hydantoin derivatives such as nitrofurantoin and the mechanism of 
action of HDPs, herein we propose to design a new class of hydantoin based small molecules, so as to 
enhance and revitalize the antibacterial activity of old antibiotics by conferring their ability for bacterial 
membrane association. It is well known that the existing lipo-antibiotics including marketed drugs 
10 
 
daptomycin107-108 and polymyxin109-110, the two “last-resort” antibiotics, all associate and interact with 
bacterial membranes using their lipid tails. Our previous findings also indicate that cationic 
peptidomimetics with lipidation could kill bacteria with greater potency by disrupting bacterial 
membranes.111-115 Thus, we hypothesized that hydantoin compounds bearing cationic groups and lipid 
tails would be membrane active, similar to the mechanism of action of HDPs (Figure 2.2, D2). As such, 
they could specifically interact with bacterial membranes and kill bacterial pathogens through bacterial 
membrane disruption. In addition, as the compounds still contain the hydantoin pharmacophore (Figure 
2.2, D1), they could also pass bacterial membranes and directly act on the potential targets such as 
DNAs and ribosomes,74-75 analogous to nitrofurantoin. The synergistic effect on bacterial killing could 
lead to a new generation of antibiotics with high potency and novel mechanisms, as well as less 
probability for resistance development. Herein, we report the design, synthesis, and investigation of 
hydantoin derivatives containing hydrophobic tails and cationic charged groups. Our studies show that 
these compounds exhibit much enhanced antimicrobial activity against both Gram-positive and Gram-
negative bacteria compared to nitrofurantoin (>50 fold for certain strains), including clinically relevant 
multidrug resistant bacterial strains. The lead compound also shows excellent in vivo activity towards 
MRSA-induced pneumonia on a rat model by eradicating MRSA and suppressing lung inflammation 
caused by pneumonia. 
 
Figure 2.2 Design of hydantoin compounds with membrane-acting capability. D1, the 
hydantoin core, in which R1 represents hydrophobic groups; D2, membrane interacting domain, 
in which R2 is the cationic group, and Cx represents lipid tails. 
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2.2 Results and Discussion 
Our attempted to design membrane-active hydantoins in a very straightforward manner, making 
it possible for convenient optimization and production in the future. As shown in Figure 2, R2 was 
designated to be cationic NH2 group, R1 were hydrophobic groups, and Cx were lipid tails. The 
synthesis was also very straightforward (Figure 2.3), which allowed a series of compounds to be 
prepared rapidly on the solid phase. Briefly, the alloc protected building block116-117 bearing the R2 side 
chain was attached to Rink-amide resin. After the alloc group was removed, the R1NCO was added to 
react with the secondary amine to introduce urea functionality. Next, the alloc protecting group was 
removed, followed by reaction with the CxCOCl to introduce the lipid tail. The molecule was then 
cleaved from the solid support in the presence of 1:1 TFA/DCM, which cyclized spontaneously in situ 
to yield the desired hydantoin product with good yield.  
 
 
Figure 2.3 The general approach to synthesize cationic lipidated hydantoins.  
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Table 2.1 Activity of cationic lipidated hydantoins.  
 
Compound 
MIC (µg/mL) 
Gram Positive Gram Negative 
MRSA MRSE VREF E. coli P. A. K. P. 
1 >50 >50 >50 >50 >50 >50 
2 >50 >50 >50 12.5 >50 >50 
3 6.25 6.25 6.25 3.12 12.5 6.25 
4 3.12 3.12 3.12 3.12 >50 12.5 
5 >50 >50 >50 >50 >50 >50 
6 12.5 25 25 6.25 25 12.5 
7 6.25 6.25 6.25 6.25 >50 12.5 
8 6.25 6.25 6.25 >50 >50 >50 
9 25 >50 >50 12.5 >50 25 
10 6.25 6.25 12.5 6.25 12.5 6.25 
11 3.12 6.25 6.25 12.5 >50 6.25 
12 3.12 25 25 >50 >50 >50 
13 6.25 6.25 12.5 6.25 12.5 6.25 
14 6.25 6.25 6.25 12.5 >50 >50 
15 3.12 3.15 6.25 >50 >50 >50 
16 >50 >50 >50 >50 >50 >50 
17 >50 >50 >50 >50 >50 >50 
18 25 25 25 12.5 12.5 12.5 
19 6.25 6.25 6.25 6.25 >50 25 
20 3.12 6.25 6.25 >50 >50 >50 
21 6.25 6.25 12.5 6.25 6.25 6.25 
22 0.5 0.5 0.5 1 1 0.78 
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Table 2.1 Continued Activity of cationic lipidated hydantoins. 
 
23 12.5 12.5 12.5 >50 >50 >50 
24 12.5 12.5 12.5 >50 >50 >50 
25 >50 >50 >50 >50 >50 >50 
26 12.5 6.25 12.5 6.25 >50 25 
 
Bacteria included in the test were Methicillin-resistant S. aureus (MRSA) (ATCC 33591), Methicillin-
resistant S. epidermidis (MRSE) (RP62A), vancomycin-resistant E. faecalis (ATCC 700802), E. coli 
(ATCC 25922), P. aeruginosa (ATCC 27853), K. pneumoniae (ATCC 13383) 113, 118. Minimum 
concentration (MIC) was measured after incubating hydantoins with bacteria for 16 h. Nitrofurantoin 
(compound 26) was included in the test as the positive control.  
 
Subsequently, these cationic hydantoin derivatives were tested for their antimicrobial activity 
against a panel of Gram-positive and Gram-negative bacteria, including multidrug-resistant clinically 
relevant strains. The compound 26, nitrofurantoin, exhibits antimicrobial activity against most of 
bacteria with MICs ranging from 6.25 to 25 µg/mL, which are highly consistent to previously reported 
antibacterial activity.79, 119 Although nitrofurantoin is the preferred antibiotic to treat bladder and urinal 
tract infections, as shown above, its antibacterial activity is moderate. It should also be noted that under 
the tested condition, nitrofurantoin failed to show any activity toward Pseudomonas aeruginosa, a 
notorious Gram-negative strain which could cause severe or even lethal infection.  
As the proof of concept, we fixed the cationic group R2 shown in Figure 2, and explored the 
activity of the compounds with respect to the variation of the hydrophobic group R1 and the lipid tail 
Cx. When R1 is the ethyl group, with a C10 decanoic tail, the compound 1 doesn’t display any activity 
against all tested bacterial strains. It could be due to insufficient hydrophobicity of the ethyl group and 
short length of the lipid tail, rendering the compound 1 ineffective to interact with bacteria. It is therefore 
reasonable to observe that the antimicrobial activity of compounds 2 and 3 increase as their lipid tails 
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become longer, which makes them more membrane active. Indeed, compound 3 already has comparable 
activity to nitrofurantoin against most strains; in addition, it shows an encouraging MIC of 12.5 µg/mL 
toward P. aeruginosa, suggesting that hydantoin compounds could be developed to identify more potent 
antibiotic agents. However, it is intriguing that the longer lipid tail doesn’t necessary lead to more potent 
antimicrobial agents. As seen for 4, which contains the same ethyl group for R1 but a C16 palmitic lipid 
tail, albeit exhibiting enhanced activity against Gram-positive bacteria, abolishes its activity toward P. 
aeruginosa. It clearly implies that both hydantoin core (D1) and membrane interacting domain (D2) are 
required for good antimicrobial activity, and a balance of hydrophobicity for R1 and lipid tail length for 
Cx is needed. With the preliminary studies on this series of ethyl-containing hydantoins, we set out to 
test the activity of a few more compounds containing R1 of increased hydrophobicity. With the 
enhanced rigidity and hydrophobicity, the compounds are more active, even though they still contain 
the C10 lipid tails. For instance, compound 5, containing the butyl group, doesn’t have any antimicrobial 
activity. However, bearing the cyclohexyl group for R1, compound 9 starts to show activity toward a 
few bacterial strains. While with the adamantyl group, compound 13 already exhibits decent activity 
across the panel of bacteria. Again, in each series of compounds bearing the same R1 group, increasing 
the length of the lipid tail lead to enhancement and then detriment in antimicrobial activity. Consistent 
to the findings in the initial investigation, it seems that the compounds containing C12 or C14 tail 
possess the optimal antimicrobial activity. As aromatic groups are frequently identified in vast majority 
of antibiotic agents, we next tested the activity of hydantoins containing phenyl groups as the R1 group. 
Although para-methoxybenzyl group-containing compounds 17-20 do not yield better antibiotic agents, 
hydantoins possessing the meta-chlorobenzyl groups lead to new compounds with potent and broad-
spectrum activity. The most potent compound 22 exhibits MICs less than 1 µg/mL against all tested 
15 
 
Gram-positive and Gram-negative strains. Compared with nitrofurantoin, it is 25-fold as effective 
toward MRSA, and at least 50-fold more effective toward P. aeruginosa. We lastly examined the impact 
of the cationic charge R2 on the antimicrobial activity. Surprisingly, replacement of the cationic 
aminobutyryl group in 22 with the phenyl group gives the highly hydrophobic compound 25, which 
fails to show any antimicrobial activity. It strongly supports that the cationic charge is of vital 
importance for antimicrobial activity, possible due to its ability for electrostatic interaction with 
negatively charged bacterial membranes. 
Table 2.2 Selectivity of hydantoin compounds.  
 
compound MIC of MRSA (µg/mL) HC50 (µg/mL) SI (MIC/HC50) 
3 6.25 90 14.4 
6 12.5 80 6.4 
10 6.25 100 16 
13 6.25 125 20 
18 25 200 8 
21 6.25 100 16 
22 0.5 95 190 
26 12.5 >200 >16 
HC50 is the hemolytic activity of the compounds. SI is selectivity index, which is the ratio of MIC for 
MRSA to hemolytic activity. Nitrofurantoin (compound 26). 
 
In order to evaluate the therapeutic potential of these hydantoin compounds, we next investigated 
the selectivity of the lead compounds which exhibited broad-spectrum antimicrobial activity against all 
tested strains. As shown in Table 2.2, these compounds all have better antimicrobial activity than 
nitrofurantoin 26, while exhibiting limited hemolytic activity. Most noticeably, the most potent 
compound 22, with much enhanced activity compared with nitrofurantoin, show excellent selectivity 
toward MRSA bacteria.  
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As aforementioned, the antimicrobial mechanisms of hydantoins are complex and elusive, 
however, since the compounds developed here were expected to at least possess the mechanism of 
action analogous to HDPs, their impact on bacterial membranes could be investigated by fluorescent 
microscopic studies. 113, 120 The most potent compound 22 was thus studied for its ability to compromise 
bacterial membranes of Gram-positive bacteria MRSA and Gram-negative bacteria E. coli.66, 121 Two 
dyes, 4',6-diamidino-2-phenylindole (DAPI), and propidium iodide (PI) (Figure 2.4), were used to 
differentiate cells with either intact or damaged membranes. DAPI could permeate intact cell membrane 
and as such it shows blue fluorescence regardless of cell viability. In contrast, PI is a DNA intercalator 
but lack of cell permeability. It only fluoresces in red color when cell membranes are disrupted. As 
shown in Figure 4, under the DAPI channel, both MRSA and E. coli exhibit blue fluorescence (Figure 
2.4a1 and 2.4a3) in the absence of the compound 22, whereas none of them display fluorescence under 
the PI channel (Figure 2.4b1 and 2.4b3), indicating the membranes of these bacteria were intact. 
However, after bacteria including both MRSA and E. coli were incubated with 22 for 2 h, they are able 
to be stained by both DAPI and PI channels (Figure 2.4a2, 2.4b2, 4a4, 4b4), suggesting the membranes 
of both MRSA and E. coli were damaged.                                                                                                    
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Figure 2.4 Fluorescence micrographs of MRSA and E. coli that were treated or not treated with 5 
µg/mL of 22 for 2 h. a1, control, no treatment, DAPI stained; b1, control, no treatment, PI stained. a2, 
MRSA treatment with 22, DAPI stained; b2, MRSA treatment with 22, PI stained. a3, control, no 
treatment, DAPI stained; b3, control, no treatment, PI stained. a4, E. coli treatment with 22, DAPI 
stained; b4, E. coli treatment with 22, PI stained. Scale bar = 10 µm. 
HDPs are well known for their ability to eradicate bacteria rapidly, due to their membrane 
disruptive bactericidal mechanism.122 It is compelling to know if our newly synthesized hydantoin 
compounds exhibit similar bacterial killing kinetics. As such, we subsequently carried out time-kill 
studies for 22 at different concentrations toward MRSA and E. coli, respectively. As shown in Figure 
2.5, at 25 and 50 µg/mL, 22 could completely eradicate MRSA in just 10 min (Figure 2.5a). Even at 
12.5 µg/mL, MRSA were thoroughly removed in 30 min. Killing E. coli is relatively slower, however, 
all bacteria were still eradicated in 30 min at all concentrations. It demonstrates that this class of 
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hydantoin compounds could rapidly kill both Gram-positive and Gram-negative pathogens, analogous 
to HDPs. 
 
Figure 2.5 Time-kill plots of 22 against MRSA (a) and E. coli (b). 
 
One of the most appealing features of HDPs is that they do not readily elicit bacteria resistance, 
as they disrupt bacterial membranes rather than acting on specific targets.123 Since compound 22 was 
designed to be membrane active, in addition to the mechanism of action due to the hydantoin core, we 
hypothesized that 22 could also prevent the resistance development in bacteria. As such, we conducted 
the drug resistance studies for 22 against MRSA. 22 were incubated with bacteria at the concentration 
of half MIC overnight, and the new MIC was measured subsequently. It is intriguing that after 14 
passages, MICs of 22 virtually remain unchanged (Figure 2.6), which strongly suggests that this class 
of hydantoin compounds do not readily induce resistance in bacteria, thereby augmenting their potential 
therapeutic applications.  
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Figure 2.6 Drug resistance study for compound 22. 
 
One of the major causes of pneumonia is bacterial infection.124 Hospital-acquired and 
community-acquired MRSA pneumonia has become more prevalent in recent years and presented 
significant therapeutic challenges due to its increasing motility.124 As our hydantoin compounds 
exhibited potent in vitro antibacterial activity against both Gram-positive and Gram-negative bacteria 
including MRSA, it was intriguing to investigate their in vivo activity so as to assess their therapeutic 
potential. As such, we tested their efficacy on a rat model bearing MRSA pneumonia induced by 
intratracheal instillation.120, 125 As shown in Figure 2.7, the control group, which was treated with PBS 
only, exhibited high level of MRSA after bacterial inoculation. The slightly decreased quantity of 
bacteria on day 5 compared with day 3 suggested that rats may fight MRSA through their host immune 
response.125 However, the impact on the bacterial clearance was very minimal. Vancomycin, which has 
long been considered as the “last-resort” antibiotic to treat infections caused by multidrug-resistant 
Gram-positive pathogens, was included as a positive control. As shown in Figure 2.7, vancomycin did 
exhibit efficacy in the inhibition of MRSA proliferation. On the day 3 after its administration, it 
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exhibited ~30% reduction of bacteria compared with the control. On the day 5, the reduction increased 
~45%. It indicates that vancomycin could help to clear MRSA from lungs of rats. However, the 
compound 22 displayed a much superior in vivo efficacy in the eradication of MRSA bacteria. On the 
day 3 after the treatment of 22, a ~70% reduction in bacteria was observed. On the day 5, compared to 
the control, MRSA was reduced by 96%. The remarkable potency of 22 relative to the control and 
vancomycin demonstrates its future therapeutic potential.        
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Figure 2.7. In vivo efficacy of the compound 22 on a rat model bearing MRSA pneumonia bearing. 
Rats (n = 6 per group) were inoculated with 100 µL of 106 CFU/mL MRSA by intratracheal instillation, 
followed by i. v. injection of 22 (10 mg/kg) in the tail vein after 24h. 
 
Given the findings that 22 could virtually completely eradiate the MRSA bacteria in lungs, we 
subsequently conducted the pathological analysis to find out if 22 could suppress lung inflammation 
induced by MRSA. As shown in Figure 8, all three groups (PBS control, vancomycin and 22) all 
demonstrate normal conditions right after MRSA inoculation (0 day), which suggests that the 
inflammation has not developed in lungs. However, the inflammation in the control group elevated 
rapidly due to the lack of treatment, as seen for the presence of heavily populated inflammatory cells 
including monocytes, macrophages, neutrophils, eosinophils, etc (blue spots in H&E staining) on the 
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day 5, which is the typical indication of severe lung pneumonia. Rats treated with vancomycin showed 
alleviated condition due to its ability to inhibit the proliferation of MRSA, which lowered down the 
inflammation. Remarkably, treatment with the compound 22 exhibited much more significant impact 
on the suppression of lung inflammation. On the day 3, only mild inflammation was observed, whilst 
on the day 5, the inflammation was further mitigated to almost the normal condition. The findings, 
consistent to the abovementioned MRSA proliferation studies, strongly suggest that the compound 22 
could be superior to vancomycin as a novel therapeutic strategy to treat MRSA pneumonia.  
 
Figure 2.8 Pathological assay based on hematoxylin and eosin (H&E) staining. 
 
2.3 Conclusions 
In summary, we have reported a new class of hydantoin derivatives as the potential antibiotic 
agents. These molecules, bearing cationic charge and hydrophobic lipid tail, were designed to be 
membrane active in bacterial killing. They exhibited significantly more potent antimicrobial activity 
against a panel of multidrug-resistant Gram-positive and Gram-negative bacteria compared with the 
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marketed antibiotic nitrofurantoin, a hydantoin derivative. Although mechanisms of action for 
hydantoin compounds are known to be complex, our investigation demonstrated that the hydantoin 
compounds reported here could compromise bacterial membranes and kill bacteria rapidly and do not 
induce resistance in MRSA even after 14 passages, which is similar to host-defense peptides (HDPs). 
Moreover, these molecules have also exhibited remarkable in vivo efficacy on a rat model bearing 
MRSA-induced pneumonia, by effectively eradicating MRSA bacteria and suppressing lung 
inflammation, which is superior to vancomycin. Together with the facile synthesis, these compounds 
could be an appealing class of antibiotic agents to combat emergent drug-resistance. Further 
optimization of lead compounds and efficacy studies on other in vivo models are currently underway. 
2.4 Experimental 
2.4.1 General information 
Rink amide MBHA resins (0.7 mmol/g, 200‒400 mesh) were purchased from Chem-Impex Int’l 
Inc. Solvents and other chemicals were ordered from either Fisher Scientific or Sigma-Aldrich, and 
were used without further purification. The 1HNMR spectra were obtained on a Varian Inova 400 
instrument. The solid phase syntheses of all compounds were carried out in a peptide reaction vessel on 
a Burrell Wrist-Action shaker. All compounds were analyzed and purified using the Waters Breeze 2 
HPLC system under 215 nm of UV detector equipped with both analytical and preparative modules. 
The desired fractions were lyophilized on a Labcono lyophilizer. Molar masses of compounds were 
identified by Agilent Technologies 6540 UHD Accurate-Mass Q-TOF LC/MS spectrometer. 
2.4.2 Synthesis of γ-AApeptide building blocks 
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Figure 2.9. γ-AApeptide building blocks. 
 
Both γ-AApeptide building blocks shown above were used in the synthesis of hydantoin compounds; 
their synthetic procedure was reported previously.126  
2.4.3 Synthesis of hydantoin compounds 
 
Figure 2.10 General synthetic procedure for hydantoin compounds.  
 
Synthetic procedure of the compound 22: 200 mg Rink-amide (MBHA) resin (0.14 mmol) was 
treated with 3 mL 20% piperidine/DMF (v/v) solution for 15 min (× 2) to remove the Fmoc protection 
group, followed by DMF (2 mL × 3) and DCM (2 mL × 3) wash. The attachment of the γ-AApeptide 
building block to the resin was achieved by adding γ-Lys-BB (238 mg, 0.4 mmol), DIC (101 mg, 114 
μL, 0.8 mmol), and HOBt (122 mg, 0.8 mmol) in 3 mL DMF to the reaction vessel, and the reaction 
was allowed to shake at room temperature for 3 h. The solution was drained, and the beads were washed 
with DCM (3 mL × 3) and DMF (3 mL × 3). After that, beads were treated with Pd(PPh3)4 (24 mg, 0.02 
mmol) and Me2NH.BH3 (70 mg, 1.2 mmol) in 3 mL DCM for 10 min (×2) to remove the alloc protein 
group, then washed with DCM (3 mL x3) and DMF (3 mL ×3). Next, 3-chlorophenyl isocyanate (77 
mg, 61 μL, 0.5 mmol) and DIPEA (65 mg, 87 μL, 0.5 mmol) in 3 mL DCM were added to the resin and 
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allowed to react for 30 min at room temperature, and then the solution was drained. After DMF (2 mL 
×3) and DCM (2 mL ×3) wash, beads were treated with 3 mL 20% piperidine/DMF (v/v) solution for 
15 min (× 2) to remove the Fmoc protection group, followed by wash with DMF (2 mL ×3) and DCM 
(2 mL ×3). Subsequently, lauric acid (80 mg, 0.4 mmol), DIC (101 mg, 114 μL, 0.8 mmol), and HOBt 
(122 mg, 0.8 mmol) in 3 mL DMF were added to the reaction vessel and reacted for 3 h. After the 
solution was drained, the beads were washed with DMF (2 mL ×3) and DCM (2 mL ×3), followed by 
the incubation with 4 mL cocktail of 1:1 TFA: DCM 1:1 (v/v) for 2 h to achieve cleavage and global 
deprotection of the compound. After the solvent was removed in vacuo, the residue was analyzed and 
purified on the Waters HPLC system, and the desired fraction was lyophilized to give the pure product 
22 which was subsequently characterized by NMR and MS. 
Synthesis of other compounds: The other compounds were synthesized following the similar 
procedure of compound 22. 
Compound 1  
1HNMR (400 MHz, d6-DMSO) δ 7.73 (brd, 3H), 7.61 (d, J=8.0Hz, 1H), 4.01 (d, J =6.8Hz, 1H), 3.81-
3.89 (m, 2H), 3.33-3.36 (m, 3H), 3.09 (dd, J = 14.0, 4.4 Hz, 1H), 2.65-2.74 (m, 2H), 1.96 (t, J = 16.0Hz, 
2H), 1.31-1.49 (m, 6H), 1.10-1.30 (m, 14H), 1.01 (t, J = 14.4Hz, 3H), 0.81 (t, J = 16.0Hz, 3H).  
13CNMR (125 MHz, d6-DMSO) δ 173.0, 170.6, 156.8, 50.3, 46.8, 46.7, 39.1, 35.9, 33.4, 31.6, 31.0, 
29.2, 29.1, 29.0, 28.9, 27.0, 25.7, 22.8, 22.5, 14.3, 13.6.   HRMS (ESI) C21H40N4O3 [M+H]+ calc’d = 
397.3175; found = 397.3176. 
Compound 2  
1HNMR (400 MHz, d6-DMSO) δ 7.70 (brd, 3H), 7.62 (d, J=8.8Hz, 1H), 3.80-4.05 (m, 3H), 3.31-3.36 
(m, 3H), 3.03 (dd, J = 14.0, 4.0 Hz, 1H), 2.67-2.75 (m, 2H), 1.97 (t, J = 7.2Hz, 2H), 1.36-1.49 (m, 6H), 
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1.10-1.25 (m, 18H), 1.02 (t, J = 7.2Hz, 3H), 0.82 (t, J = 6.4Hz, 3H).   13CNMR (125 MHz, d6-DMSO) 
δ 173.0, 170.7, 156.8, 50.3, 46.9, 46.7, 36.0, 33.4, 31.7, 31.0, 29.4, 29.4, 29.3, 29.2, 29.1, 29.0, 27.7, 
25.7, 22.8, 22.5, 14.3, 13.7.  HRMS (ESI) C23H44N4O3 [M+H]+ calc’d = 425.3485; found = 425.3486. 
Compound 3  
1HNMR (400 MHz, d6-DMSO) δ 7.75 (brd, 3H), 7.63 (d, J=8Hz, 1H), 4.02 (d, J =17.2Hz, 1H), 3.85 (d, 
J =17.2Hz, 1H), 3.31-3.33 (m, 3H), 3.03 (dd, J = 14.0, 4.0 Hz, 1H), 2.70-2.73 (m, 2H), 1.97 (t, J = 
7.2Hz, 2H), 1.29-1.48 (m, 8H), 1.10-1.24 (m, 22H), 1.02 (t, J = 7.2Hz, 3H), 0.82 (t, J = 6.4Hz, 3H).  
13CNMR (125 MHz, d6-DMSO) δ 172.8, 170.7, 156.8, 50.3, 46.9, 46.7, 39.3, 39.1, 36.0, 33.4, 31.7, 
31.1, 29.4, 29.3, 29.2, 29.1, 29.0, 27.1, 25.7 22.9, 22.5, 14.4, 13.7.  HRMS (ESI) C25H48N4O3 [M+H]+ 
calc’d = 453.3799; found = 453.3800. 
Compound 4  
1HNMR (400 MHz, d6-DMSO) δ 7.77 (brd, 3H), 7.62 (d, J=9.2Hz, 1H), 3.79-4.09 (m, 3H), 3.30-3.37 
(m, 3H), 3.08 (dd, J = 14.0, 4.0 Hz, 1H), 2.65-2.75 (m, 2H), 1.96 (t, J = 7.6Hz, 2H), 1.27-1.53 (m, 6H), 
1.03-1.24 (m, 26H), 1.01 (t, J = 7.2Hz, 3H), 0.81 (t, J = 6.4Hz, 3H).  13CNMR (125 MHz, d6-DMSO) 
δ 172.8, 170.6, 156.8, 50.3, 46.9, 46.7, 39.1, 36.0, 33.4, 31.7, 31.1, 29.5, 29.3, 29.2, 29.1, 29.1, 27.1, 
25.7 22.9, 22.5, 14.4, 13.7.   HRMS (ESI) C27H52N4O3 [M+H]+ calc’d = 481.4112; found = 481.4110. 
Compound 5 
1HNMR (400 MHz, d6-DMSO) δ 7.72 (brd, 3H), 7.62 (d, J=8.8Hz, 1H), 3.85 (d, J = 17.2Hz, 2H), 3.26-
3.45 (m, 3H), 3.00-3.15 (m, 1H), 2.68-2.73 (m, 2H), 1.96 (t, J = 14.8Hz, 2H), 1.32-1.52 (m, 8H), 1.10-
1.25 (m, 16H), 0.79-0.83 (m, 6H).  13CNMR (125 MHz, d6-DMSO) δ 173.0, 170.9, 157.0, 50.2, 46.9, 
46.7, 39.2, 38.1, 36.0, 31.7, 31.0, 30.1, 29.3, 29.2, 29.1, 29.0, 27.1, 25.7, 22.8, 22.5, 19.7, 14.3 13.8.   
HRMS (ESI) C23H44N4O3 [M+H]+ calc’d = 425.3486; found = 425.3487. 
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Compound 6  
1HNMR (400 MHz, d6-DMSO) δ 7.75 (brd, 3H), 7.62 (d, J=9.2Hz, 1H), 4.02 (d, J=17.2Hz 1H), 3.82-
3.94 (m, 2H), 3.25-3.39 (m, 3H), 3.07 (dd, J = 14.0, 4.0 Hz, 1H), 2.68-2.74 (m, 2H), 1.96 (t, J = 7.6Hz, 
2H), 1.29-1.51 (m, 8H), 1.10-1.22 (m, 20H), 0.79-0.84 (m, 6H).  13CNMR (125 MHz, d6-DMSO) δ 
172.8, 170.8, 156.9, 50.2, 46.9, 46.7, 39.1, 38.1, 36.0, 31.7, 31.1, 30.1, 29.5, 29.4, 29.3, 29.2, 29.1, 27.1, 
25.7, 22.9, 22.5, 19.7, 14.4, 13.9.   HRMS (ESI) C25H48N4O3 [M+H]+ calc’d = 453.3802; found = 
453.3803. 
Compound 7  
1HNMR (400 MHz, d6-DMSO) δ 7.73 (brd, 3H), 7.62 (d, J=8.8Hz, 1H), 4.02 (d, J=17.6Hz 1H), 3.82-
3.90 (m, 2H), 3.26-3.38 (m, 3H), 3.07 (dd, J = 14.0, 4.0 Hz, 1H), 2.68-2.74 (m, 2H), 1.95 (t, J = 7.2Hz, 
2H), 1.30-1.54 (m, 8H), 1.12-1.25 (m, 24H), 0.78-0.84 (m, 6H).  13CNMR (125 MHz, d6-DMSO) δ 
172.8, 170.8, 156.9, 50.2, 46.9, 46.7, 39.1, 38.1, 36.0, 31.7, 31.1, 30.1, 29.5, 29.3, 29.2, 29.1, 27.1, 25.7, 
22.9, 22.5, 19.7, 14.3, 13.9.    HRMS (ESI) C27H52N4O3 [M+H]+ calc’d = 481.4112; found = 481.4111. 
Compound 8  
1HNMR (400 MHz, d6-DMSO) δ 7.77 (brd, 3H), 7.62 (d, J=9.2Hz, 1H), 4.02 (d, J=17.2Hz 1H), 3.82-
3.89 (m, 2H), 3.25-3.38(m, 3H), 3.07 (dd, J = 13.6, 4.0 Hz, 1H), 2.68-2.73 (m, 2H), 1.95 (t, J = 7.2Hz, 
2H), 1.27-1.50 (m, 8H), 1.08-1.22 (m, 28H), 0.79-0.84 (m, 6H).   13CNMR (125 MHz, d6-DMSO) δ 
173.0, 170.8, 157.0, 50.1, 46.9, 46.7, 38.1, 36.0, 31.7, 31.1, 30.1, 29.4, 29.3, 29.2, 29.1, 27.1, 25.7, 22.8, 
22.5, 19.7, 14.3, 13.8.  HRMS (ESI) C29H56N4O3 [M+H]+ calc’d = 509.4422; found = 509.4424. 
Compound 9  
1HNMR (400 MHz, d6-DMSO) δ 7.66 (brd, 3H), 7.59 (d, J=8.8Hz, 1H), 3.95-3.98 (m, 1H), 3.73-3.85 
(m, 2H), 3.61-3.72(m, 1H), 3.29-3.35 (m, 1H), 3.03-3.08 (m, 1H), 2.65-2.72 (m, 2H), 1.93-1.98 (m, 
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4H), 1.72 (d, J=12.4Hz, 2H), 1.28-1.57 (m, 8H), 1.02-1.24 (m, 18H), 0.82 (t, J=6.8Hz, 3H).  13CNMR 
(125 MHz, d6-DMSO) δ 172.9, 170.8, 156.7, 50.9, 49.8, 46.9, 46.6, 36.0, 31.7, 31.0, 29.4, 29.4, 29.2, 
29.2, 29.1, 27.1, 25.7, 25.2, 22.8, 22.5, 14.3.   HRMS (ESI) C25H46N4O3 [M+H]+ calc’d = 451.3643; 
found = 451.3644. 
Compound 10  
1HNMR (400 MHz, d6-DMSO) δ 7.64 (brd, 3H), 7.60 (d, J=9.2Hz, 1H), 3.95-4.05 (m, 3H), 3.34-3.36 
(m, 1H), 3.25 (s, 1H), 3.00-3.09 (m, 1H), 2.71 (s, 2H), 1.90-2.00 (m, 4H), 1.72 (d, J=12.4Hz, 2H), 1.31-
1.59 (m, 8H), 1.00-1.27 (m, 22H), 0.82 (t, J=6.0Hz, 3H).  13CNMR (125 MHz, d6-DMSO) δ 173.2, 
170.8, 156.7, 50.9, 49.8, 46.9, 46.6, 36.0, 31.7, 31.1, 29.4, 29.4, 29.3, 29.1, 27.1, 25.8, 25.3, 22.5.   
HRMS (ESI) C27H50N4O3 [M+H]+ calc’d = 479.3955; found = 479.3956. 
Compound 11  
1HNMR (400 MHz, d6-DMSO) δ 7.72 (brd, 3H), 7.60 (d, J=9.2Hz, 1H), 3.92-4.00 (m, 1H), 3.61-3.85 
(m, 2H), 3.25-3.36 (m, 2H), 3.01-3.10 (m, 1H), 2.68-2.71 (m, 2H), 1.91-2.01 (m, 4H), 1.72 (d, J=12.4Hz, 
2H), 1.30-1.58 (m, 8H), 0.98-1.25 (m, 26H), 0.82 (t, J=6.4Hz, 3H).  13CNMR (125 MHz, d6-DMSO) 
δ 172.7, 170.6, 156.7, 50.9, 49.8, 46.9, 46.6, 39.1, 36.1, 31.7, 31.1, 29.5, 29.4, 29.3, 29.2, 29.1, 27.1, 
25.8, 25.2, 22.9, 22.5, 14.3.   HRMS (ESI) C29H54N4O3 [M+H]+ calc’d = 507.4269; found = 507.4272. 
Compound 12  
1HNMR (400 MHz, d6-DMSO) δ 7.77 (brd, 3H), 7.61 (d, J=9.2Hz, 1H), 3.96 (d, J=12.4Hz, 1H), 3.63-
3.81 (m, 2H), 3.28-3.33 (m, 2H), 3.00-3.10 (m, 1H), 2.62-2.75 (m, 2H), 1.91-1.99 (m, 4H), 1.70 (d, 
J=12.0Hz, 2H), 1.31-1.59 (m, 8H), 0.99-1.24 (m, 30H), 0.81 (t, J=6.4Hz, 3H).  13CNMR (125 MHz, 
d6-DMSO) δ 173.1, 170.7, 156.7, 51.0, 49.8, 46.9, 46.6, 36.1, 31.7, 31.0, 29.4, 29.3, 29.2, 29.1, 27.0, 
25.8, 25.2, 22.8, 22.5, 14.3.   HRMS (ESI) C31H58N4O3 [M+H]+ calc’d = 535.4582; found = 535.4583. 
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Compound 13  
1HNMR (400 MHz, d6-DMSO) δ 7.76 (brd, 3H), 7.58 (d, J=9.2Hz, 1H), 3.65-3.88 (m, 3H), 3.26-3.33 
(m, 1H), 2.99 (dd, J = 14.0, 4.0 Hz, 1H), 2.68-2.74 (m, 2H), 2.27  (d, J = 2.4 Hz, 6H), 1.93-2.03 (m, 
5H), 1.59 (s, 6H), 1.26-1.51 (m, 6H), 1.15-1.23 (m, 14H), 0.81 (t, J=7.2Hz, 3H). 13CNMR (125 MHz, 
d6-DMSO) δ 172.7, 171.5, 157.3, 59.1, 49.7, 46.7, 46.5, 39.1, 36.2, 36.1, 31.7, 31.2, 29.5, 29.3, 29.2, 
27.1, 25.8, 22.9, 22.5, 14.3.   HRMS (ESI) C29H50N4O3 [M+H]+ calc’d = 503.3955; found = 503.3955. 
Compound 14  
1HNMR (400 MHz, d6-DMSO) δ 7.70 (brd, 3H), 7.57 (d, J=9.2Hz, 1H), 3.85 (d, J = 17.2 Hz, 2H), 3.67 
(d, J = 17.2Hz, 1H), 3.26-3.33 (m, 1H), 2.99 (dd, J = 14.0, 4.0 Hz, 1H), 2.66-2.73 (m, 2H), 2.27 (d, J = 
2.4 Hz, 6H), 1.95-2.01 (m, 5H), 1.59 (s, 6H), 1.26-1.51 (m, 6H), 1.12-1.23 (m, 18H), 0.81 (t, J=6.4Hz, 
3H).  13CNMR (125 MHz, d6-DMSO) δ 172.9, 171.5, 157.3,59.1, 49.6, 46.6, 46.5, 36.2, 36.1, 31.7, 
31.2, 29.5, 29.4, 29.3, 29.3, 29.2, 29.1, 27.1, 25.8, 22.9, 22.5 14.3.   HRMS (ESI) C31H54N4O3 [M+H]+ 
calc’d = 531.4269; found = 531.4269. 
Compound 15  
1HNMR (400 MHz, d6-DMSO) δ 7.72 (brd, 3H), 7.57 (d, J=9.2Hz, 1H), 3.85 (d, J = 17.2 Hz, 2H), 3.68 
(d, J = 17.2Hz, 1H), 3.27-3.34 (m, 1H), 2.99 (dd, J = 14.0, 4.0 Hz, 1H), 2.66-2.74 (m, 2H), 2.27 (d, J = 
2.4 Hz, 6H), 1.94-2.01 (m, 5H), 1.59 (s, 6H), 1.26-1.50 (m, 6H), 1.13-1.22 (m, 22H), 0.81 (t, J=6.4Hz, 
3H).  13CNMR (125 MHz, d6-DMSO) δ 172.9, 171.5, 157.3,59.1, 49.6, 46.6, 46.5, 39.1, 36.1, 36.1, 
31.7, 31.1, 29.5, 29.4, 29.4, 29.3, 29.3, 29.2, 29.1, 27.1, 25.8, 22.8, 22.5, 14.3.   HRMS (ESI) 
C33H58N4O3 [M+H]+ calc’d = 559.4578; found = 559.4579. 
Compound 16  
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1HNMR (400 MHz, d6-DMSO) δ 7.63 (brd, 3H), 7.57 (d, J=8.8Hz, 1H), 3.85 (d, J = 17.2 Hz, 2H), 3.68 
(d, J = 17.2Hz, 1H), 3.25-3.33 (m, 1H), 2.99 (dd, J = 14.0, 4.0 Hz, 1H), 2.68-2.73 (m, 2H), 2.27 (d, J = 
2.4 Hz, 6H), 1.92-2.02 (m, 5H), 1.60 (s, 6H), 1.24-1.50 (m, 6H), 1.10-1.20 (m, 26H), 0.81 (t, J=7.2Hz, 
3H).  13CNMR (125 MHz, d6-DMSO) δ 172.9, 171.5, 157.3,59.1, 49.6, 46.6, 46.4, 39.1, 36.1, 36.1, 
31.7, 31.1, 29.5, 29.4, 29.3, 29.3, 29.2, 29.1, 27.1, 25.8, 22.8, 22.5, 14.3.   HRMS (ESI) C35H62N4O3 
[M+H]+ calc’d = 587.4895; found = 587.4897. 
Compound 17  
1HNMR (400 MHz, d6-DMSO) δ 7.74 (brd, 3H), 7.68 (d, J=8.8Hz, 1H), 7.16 (d, J=9.2Hz, 2H), 6.97 (d, 
J=8.8Hz, 2H), 4.18 (d, J=17.2Hz, 1H), 3.92-4.03 (m, 2H), 3.74 (s, 3H), 3.36-3.42 (m, 1H), 3.17 (dd, J 
= 14.0, 4.0 Hz, 1H), 2.68-2.76 (m, 2H), 1.99 (t, J = 7.2 Hz, 2H), 1.29-1.54 (m, 6H), 1.06-1.25 (m, 14H), 
0.80 (t, J=6.0Hz, 3H).  13CNMR (125 MHz, d6-DMSO) δ 173.1, 170.1, 159.0, 156.2, 128.2, 125.2, 
114.4, 55.8, 50.4, 47.2, 46.8, 36.1, 31.7, 31.0, 29.3, 29.1, 27.1, 25.8, 22.9, 22.5, 14.4.   HRMS (ESI) 
C26H42N4O3 [M+H]+ calc’d = 475.3279; found = 475.3279. 
Compound 18  
1HNMR (400 MHz, d6-DMSO) δ 7.78 (brd, 3H), 7.68 (d, J=8.8Hz, 1H), 7.16(d, J=9.2Hz, 2H), 6.96(d, 
J=9.2Hz, 2H), 4.18 (d, J=17.2Hz, 1H), 3.90-4.03 (m, 2H), 3.74 (s, 3H), 3.37-3.43 (m, 1H), 3.13-3.20 
(m, 1H), 2.65-2.80 (m, 2H), 1.99 (t, J = 7.2 Hz, 2H), 1.29-1.53 (m, 6H), 1.07-1.24 (m, 18H), 0.80 (t, 
J=6.0Hz, 3H).  13CNMR (125 MHz, d6-DMSO) δ 173.1, 170.0, 158.9, 156.2, 128.2, 125.2, 114.5, 55.7, 
50.4, 47.2, 46.8, 39.1, 36.0, 31.7, 31.0, 29.5, 29.4, 29.3, 29.2, 29.1, 27.1, 25.8, 22.8, 22.5, 14.3.   
HRMS (ESI) C28H46N4O3 [M+H]+ calc’d = 503.3592; found = 503.3594 
Compound 19  
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1HNMR (400 MHz, d6-DMSO) δ 7.77 (brd, 3H), 7.68 (d, J=9.2Hz, 1H), 7.16 (d, J=9.2Hz, 2H), 6.97 (d, 
J=9.2Hz, 2H), 4.19 (d, J=17.2Hz, 1H), 3.91-4.03 (m, 2H), 3.74 (s, 3H), 3.37-3.43 (m, 1H), 3.15-3.21 
(m, 1H), 2.70-2.76 (m, 2H), 2.00 (t, J = 7.2 Hz, 2H), 1.30-1.57 (m, 6H), 1.10-1.24 (m, 22H), 0.82 (t, 
J=6.4Hz, 3H).  13CNMR (125 MHz, d6-DMSO) δ 172.9, 170.0, 159.0, 156.2, 128.2, 125.3, 114.4, 55.8, 
50.4, 47.2, 46.7, 39.1, 36.1, 31.7, 31.1, 29.5, 29.5, 29.4, 29.3, 29.1, 27.1, 25.8, 22.9, 22.5, 14.4.   
HRMS (ESI) C23H44N4O3 [M+H]+ calc’d = 531.3896; found = 531.3894. 
Compound 20  
1HNMR (400 MHz, d6-DMSO) δ 7.76 (brd, 3H), 7.68 (d, J=9.2Hz, 1H), 7.15 (d, J=9.2Hz, 2H), 6.96 (d, 
J=9.2Hz, 2H), 4.18 (d, J=17.2Hz, 1H), 3.88-4.04 (m, 2H), 3.73 (s, 3H), 3.39-3.43 (m, 1H), 3.14-3.20 
(m, 1H), 2.65-2.78 (m, 2H), 1.99 (t, J = 7.2 Hz, 2H), 1.29-1.53 (m, 6H), 1.10-1.24 (m, 26H), 0.81 (t, 
J=6.4Hz, 3H).  13CNMR (125 MHz, d6-DMSO) δ 173.1, 170.0, 158.9, 156.2, 128.2, 125.2, 114.3, 55.7, 
50.4, 47.2, 46.7, 39.1, 36.0, 31.7, 31.0, 29.4, 29.4, 29.3, 29.2, 29.1, 27.1, 25.8, 22.8, 22.5, 14.3.    
HRMS (ESI) C32H54N4O3 [M+H]+ calc’d = 559.4218; found = 559.4217. 
Compound 21  
1HNMR (400 MHz, d6-DMSO) δ 7.74 (brd, 3H), 7.69 (d, J=8.8Hz, 1H), 7.29-7.50 (m, 4H), 4.01-4.25 
(m, 2H), 3.32-3.47 (m, 2H), 3.13-3.21 (m, 1H), 2.73 (s, 2H), 1.99 (t, J = 7.2 Hz, 2H), 1.26-1.51 (m, 8H), 
1.05-1.21 (m, 12H), 0.78 (t, J=6.4Hz, 3H).  13CNMR (125 MHz, d6-DMSO) δ 173.0, 169.6, 155.4, 
134.0, 133.2, 130.8, 128.0, 126.3, 125.2, 50.4, 47.3, 46.6, 36.0, 31.7, 31.0, 29.3, 29.1, 27.1, 25.8, 22.9, 
22.5, 14.4.   HRMS (ESI) C25H39N4O3 [M+H]+ calc’d = 479.2779; found = 479.2782. 
Compound 22  
1HNMR (400 MHz, d6-DMSO) δ 7.72 (brd, 3H), 7.68-7.72 (m, 1H), 6.78-7.50 (m, 4H), 3.73-4.25 (m, 
3H), 3.36-3.44 (m, 1H), 3.01-3.21 (m, 1H), 2.72 (s, 2H), 1.97-2.07 (m, 2H), 1.30-1.50 (m, 6H), 1.11-
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1.23 (m, 18H), 0.81 (t, J=6.8Hz, 3H).  13CNMR (125 MHz, d6-DMSO) δ 173.0, 169.8, 155.6, 134.0, 
133.2, 130.8, 128.0, 126.3, 125.2, 50.4, 47.3, 46.6, 39.1, 36.0, 31.7, 31.0, 29.5, 29.4, 29.3, 29.3, 29.1, 
27.1, 25.8, 22.9, 22.5, 14.4.   HRMS (ESI) C27H43N4O3 [M+H]+ calc’d = 507.3092; found = 507.3095 
Compound 23  
1HNMR (400 MHz, d6-DMSO) δ 7.69-7.73 (m, 1H), 7.67 (brd, 3H), 7.15-7.50 (m, 4H), 3.87-4.28 (m, 
3H), 3.34-3.45 (m, 1H), 3.13-3.25 ( m, 1H), 2.72 (s, 2H), 1.91-2.15 (m, 2H), 1.27-1.49 (m, 6H), 1.09-
1.20 (m, 22H), 0.81 (t, J=6.4Hz, 3H).  13CNMR (125 MHz, d6-DMSO) δ 173.2, 169.6, 155.4, 133.9, 
133.2, 130.8, 128.0, 126.3, 125.2, 50.3, 47.2, 46.6, 39.1, 36.0, 31.7, 31.0, 29.4, 29.2, 29.2, 29.1, 27.0, 
25.8, 22.8, 22.5, 14.3.  HRMS (ESI) C29H47N4O3 [M+H]+ calc’d = 535.3408; found = 535.3410. 
Compound 24  
1HNMR (400 MHz, d6-DMSO) δ 7.67 (d, J=8.8Hz, 1H), 7.63 (brd, 3H), 7.28-7.49 (m, 4H), 3.90-4.24 
(m, 2H), 3.33-3.44 (m, 2H), 3.15-3.21 (m, 1H), 2.72 (s, 2H), 1.99 (m, J=7.6Hz, 2H), 1.30-1.52 (m, 6H), 
1.10-1.22 (m, 26H), 0.81 (t, J=6.4Hz, 3H).  13CNMR (125 MHz, d6-DMSO) δ 173.1, 169.6, 155.4, 
133.9, 133.2, 130.8, 128.0, 126.3, 125.2, 50.4, 47.2, 46.6, 39.2, 36.0, 31.7, 31.0, 29.4, 29.4, 29.3, 29.2, 
29.1, 27.1, 25.8, 22.9, 22.5, 14.4.  HRMS (ESI) C31H51N4O3 [M+H]+ calc’d = 563.3722; found = 
563.3723. 
Compound 25  
1HNMR (400 MHz, d6-DMSO) δ 7.79 ( d, J=9.2Hz, 1H), 7.36-7.50 (m, 3H), 7.30 (d, J=8.0Hz, 1H), 
7.22 ( d, J=4.4Hz, 4H), 7.10-7.17 (m, 1H), 4.18-4.27 (m, 2H), 4.04 (d, J=17.6Hz, 1H), 3.47-3.54 (m, 
1H), 3.31-3.27 (m, 1H), 2.76-2.82 (m, 1H), 2.60-2.68 (m, 1H), 1.82-1.95 (m, 2H), 1.02-1.32 (m, 18H), 
0.81 (t, J=6.8Hz, 3H).   13CNMR (125 MHz, d6-DMSO) δ 172.8, 169.6, 155.5, 138.9, 134.0, 133.2, 
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130.8, 129.4, 128.5, 128.0, 126.5, 126.4, 125.3, 50.4, 48.5, 47.2, 40.8, 37.7, 36.0, 31.7, 29.4, 29.4, 29.2, 
29.1, 28.9, 25.7, 22.5, 14.4.   HRMS (ESI) C31H51N4O3 [M+H]+ calc’d = 526.2826; found = 526.2849. 
2.4.4 Minimum inhibitory concentrations (MICs) assay.127 
All compounds were tested against six different bacteria strains: methicillin-resistant S. aureus 
(MRSA, ATCC 33591), E. coli (ATCC 25922), methicillin-resistant S. epidermidis (MRSE, RP62A), 
K. pneumoniae (ATCC 13383), vancomycin-resistant Enterococcus faecalis (VREF, ATCC 700802), P. 
aeruginosa (ATCC 27853). One colony of each bacteria was inoculated in 4 mL TSB buffer at 37 °C 
overnight, which was then diluted 100 times, and the bacteria were allowed to grow to the mid-
logarithmic phase. 50 µL hydantoin compounds in 2-fold serial dilution of TSB were added in the 96-
well plate, then 50 µL diluted bacterial in TSB medium (1 × 106 CFU/mL) was added to each well. 
After 16 h of incubation at 37 °C, the absorption at 600 nm wavelength on a Biotek Synergy HT 
microtiter plate reader was recorded. Minimum inhibitory concentrations were determined as the lowest 
concentrations that inhibited bacteria growth completely. 
2.4.5 Time kill assay.127 
Bacteria MRSA (Gram-positive) and E. coli (Gram-negative) suspensions were allowed to grow 
at 37 °C to the mid-logarithmic phase, and diluted to 1 × 106 CFU/mL, then incubated with the 
compound 22 at the concentration of 50, 25, 12.5 µg/mL at 10 min, 30 min, 1 h and 2 h, respectively. 
The resulted mixture was then diluted by 102 to 104 fold, from which 100 µL was spread on the TSB 
agar plate. The Number of bacteria colonies was counted after 20 h of incubation at 37 °C.  
2.4.6 Drug resistance assay.128 
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The lead compound 22 was chosen for drug resistance studies. Briefly, after its MIC against 
MRSA was determined, the bacteria solution from the well of the 1/2 MIC was withdrawn and diluted 
to 1 × 106 CFU/mL for the next MIC measurement. The measurement was repeated for 14 passages. 
2.4.7 Hemolytic assay.127 
Fresh red blood cells (RBCs) of mice were washed with 1× PBS buffer and centrifuged 10 min 
at 3500 rpm for 3 times until the supernatant was clear, then RBCs were diluted into 5% v/v suspension 
in 1× PBS. 50 µL compounds in PBS were 2-fold serially diluted in a 96-well plate, and incubated with 
50 µL RBCs suspension for 1 h at 37 °C. The mixture was then centrifuged for 10 min at 3500 rpm. 
Subsequently, 30 µL of the supernatant was added to 100 µL PBS, then the absorbance of mixture was 
read on a Biotek Synergy HT plate reader at 540 nm. The hemolytic activity was calculated by the 
formula % hemolysis = (Abssample-AbsPBS) / (AbsTriton-AbsPBS) × 100%. 1% Triton X-100 were used as 
the positive control and 1× PBS buffer was used as the negative control. 
2.4.8 Fluorescence microscopy.127 
Both propidium iodide (PI) and 4’, 6’-diamidino-2-phenylindole dihydrochloride (DAPI) 
fluorescent dyes were used in the studies to determine the ability of the compound 22 to compromise 
the membranes of MRSA and E. coli, respectively. In brief, bacterial suspensions were incubated at 
37 °C to the mid-logarithmic phase and then diluted by 100 fold, followed by incubation with compound 
22 for 2 h at 37 °C. After centrifugation for 15 min at 5000 rpm, cell pellets were washed with 1× PBS 
buffer, and incubated with PI (5 µg/mL) for 15 min on ice in the dark, then washed 2 times with PBS. 
Then the cell pellets were incubated with DAPI (10 µg/mL) in the similar way. The pellets were then 
diluted in 100 µL PBS, and 10~20 µL of the suspension was applied on chamber slides and observed 
under Zeiss Axio Image Zloptical microscope using 100× oil-immersion objective. 
34 
 
2.4.9 In vivo study 
2.4.9.1 The rat model of MRSA-induced pneumonia.125, 129  
The protocol of animal studies was approved by the institutional committee for animal care of 
Nanjing University, and the experiments were conducted following the regulation of the National 
Ministry of Health of China. In Brief, male Wistar rats (6-8 weeks, ~200 g in average weight) were 
subjected to fast for 12 h. Next, rats were anesthetized by intraperitoneal administration of 0.35 g/kg of 
chloral hydrate. To induce MRSA pneumonia, the trachea of rats were exposed, to which 100 μL PBS 
containing 2 × 106 CFU/mL MRSA in PBS was slowly injected. The rats were retained upright for 1 
min, and the cut was sealed. The MRSA infection was allowed to develop for 24 h.  
2.4.9.2 Bronchoalveolar lavage (BAL) assay.  
The assay was carried out to quantify the bacteria in the lungs of rats. The thorax of rats was 
opened, and the lungs were collected in each group at different time points. Then the lungs were 
malleated and homogenized by a glass homogenizer, and diluted with PBS to the determined volume. 
After that, 10 μL solution was picked up, diluted with PBS by 100-fold, and daubed on the isolation 
medium. Bacteria were counted in each sample after incubation for 24 h at 37 °C, from which the 
number of bacteria (colonies/g tissue) was calculated. 
2.4.9.3 Pathological analysis.  
The hydantoin compound 22 or vancomycin were used as antibiotics in the study. In brief, a dose 
of 10 mg/kg of the drug was injected to the tested rats intravenously. On the day of 3 and 5, rats were 
sacrificed, and lung sections were stained with hematoxylin and eosin (H&E), and their morphology 
was investigated under a light microscope at 100 × magnification. The existence (indicated by the 
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infiltration of neutrophils) and the extent of possible inflammatory response (indicated by the integrity 
of the alveolar structure and endothelium cilium) were recorded from at least five randomly picked 
sections by an experienced physician. 
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CHAPTER 3: POLYMYXIN MIMIC CYCLIC PEPTIDES AS BROAD-SPECTRUM 
ANTIBIOTIC AGENTS 
3.1 Introduction 
Polymyxins were secondary metabolite nonribosomal peptides produced by Paenibacillus 
polymyxa and first recognized as antibiotic agents in the 1940s.130 Among five polymyxins (polymyxins 
A to E), two of them have been used in clinic: polymyxin B and E (also known as colistin).131 Both 
polymyxin B and colistin exhibit antibacterial activities against a narrow spectrum of gram-negative 
pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae.132  
Colistin is a complex, multicomponent antibiotic mixture.133 Two major constituents are colistin A and 
colistin B, with identical head groups but fatty acyl tails of different lengths: colistin A fatty acid is 6-
methyloctanoic acid, colistin B fatty acid is 6-methylheptanoic acid.134 In the clinical setting, colistin is 
administered in the form of colistin methane sulfonate (CMS), a less toxic and nonactive prodrug.135 
Because the early clinical experience, before the 1970s, with parenteral administration of PMB and 
colistin (or its nonactive prodrug colistin methanesulfonate) led to concern over the potential for 
nephrotoxicity and neurotoxicity, their clinical use waned.136-138 
The outer membrane of Gram-negative bacteria constitutes a permeable barrier.139 Polymyxin can 
directly interact with the lipid A component of the lipopolysaccharide (LPS).140 The current 
understanding of structure-activity relationship(SAR) is that amphipathic nature of polymyxin is 
crucial141: cationic residues and hydrophobic groups. There are several key domains crucial for 
interaction with lipid A: Dab side chain with positive charge, the heptapeptide backbone, hydrophobic 
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fatty acyl tail at N-terminal and hydrophobic motif at position 6 and 7. (figure 3.1) 
(a) 
 
(b) 
 
Figure 3.1 (a)Structure of colinstin (polymyxin E); (b)Structure of polymyxin. (Adapted with 
permission from Future Medicine. Copyright 2013.) 
 
The WHO has identified antibiotic resistance as one of the three greatest threats to human 
health.142 The world is now facing an enormous threat from the emergence of bacteria that are resistant 
to almost all available antibiotics.143 In recent years, virtually no novel drugs targeting multidrug-
resistant (MDR) Gram-negative bacteria (especially P. aeruginosa, A. baumannii and K. pneumoniae) 
have been developed.141 Meanwhile, the polymyxins are increasingly being used as last-line therapy to 
treat otherwise untreatable serious infections caused by gram-negative bacteria that are resistant to 
essentially all other currently available antibiotics.131, 144-146 However, emergence of polymyxin 
resistance in Gram-negative bacteria has been reported.147-148 The most common way that gram-negative 
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bacteria survives from polymyxin by remodeling LPS.149    
Increasing drug resistance bring emergent demand of new antibiotic agents , no new antibiotics 
will be available for these ‘superbugs’ in the near future due to the dry antibiotic discovery pipeline.150 
Over the last 30 years only two novel antibiotic classes have been introduced into the clinic (linezolid 
and daptomycin), illustrating that the post-antibiotic era is fast approaching.151 In the ‘Bad Bugs, No 
Drugs’ era, we must pursue structure–activity relationship-based approaches to develop novel 
polymyxin-like lipopeptides targeting polymyxin-resistant Gram-negative ‘superbugs’.152 
According to our previous antimicrobial peptides study, Ύ-AApeptides and long lipid tail can 
increase the stability and activity. Therefore, we set out to design a new class of polymyxin mimic cyclic 
peptides with antimicrobial activity against both Gram-positive and Gram-negative bacteria.  
3.2 Results and discussion 
According to our previous antibiotic agent study, we found out that long lipid tails and γ-
AApeptides can increase antimicrobial activity and stability of antibiotic drugs. Therefore, we set out a 
class of polymyxin mimic cyclic peptides to obtain better potent antibiotic. As Table 3.1 showed, we 
made a few changes of colinstin domains. First, we changed the length of fatty acyl group was changed 
from 8 carbons to 16 carbons to get compound P1. Secondly, to design compound P2, L-Dab residues 
on position 8 and 9 were changed to γ-AA Lys-BB-1, which contains two positive charged groups acting 
the same as L-Dab residues. For compound P3, we changed L-Dab and L-Thr residues on position 1 
and 2 to γ-AA Lys-BB-2, which contains one positive charged and one negative charged group. At last, 
we designed compound P4, with a change from D-Leu and L-Leu residues to γ-AA Leu-BB. The length 
of fatty acyl groups of compound P2, P3 and P4 are all changed to 16 carbons. According to the SAR 
of polymyxin, positive charged group will contact by electrostatic effect with negative charged groups 
39 
 
on bacteria outer membrane. Hydrophobic groups then help the molecule get through, penetrate and 
destruct the membrane.  
Table 3.1. Structures of polymyxin mimic cyclic peptides. 
Compound Change Position Change Structure 
Fatty acyl 
group 
P1 None None C16H31O 
P2 8,9 
 
C16H31O 
P3 1,2 
 
C16H31O 
P4 6,7 
 
C16H31O 
 
The antimicrobial activity was tested by MIC using 6 different bacterial strains including both 
Gram-positive and Gram-negative, results shown in Table 3.1 As mentioned in introduction, traditional 
polymyxin is only active against Gram-negative bacterial strains and does not have activity against 
Gram-positive bacteria strains. According to MIC results, all 4 polymyxin mimic cyclic peptides are 
active against both MRSA and E.coli, which indicates that increasing the length of lipid tail rationally 
will lead compounds to a broad-spectrum antibiotics. Since all 4 compounds have longer lipid tails 
compared with polymyxin. Compound P1 has good antibiotic activity against MRSA, MRSE, VREF, 
E. coli and P.A. bacteria strains. Compound P2-P4 also have broader antibacterial activity than 
polymyxin. Considering compound P1 has the best activity among 4 compounds and not contain 
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changes of γ-AApeptide building blocks, the unique backbone of γ-AApeptide doesn’t improve the 
antibiotic activity in this case. However, γ-AApeptide can still increase the chemodivisity of compounds.  
Hemolytic activity of all 4 compounds was also investigated. As shown in Table X, all 4 compounds 
exhibit limited hemolytic activity and compound P1 has good selectivity toward MRSA.  
Table 3.2 Activity and selectivity of polymyxin mimic peptides.  
Compound 
MIC (µg/mL) 
Hemolytic 
Activity Gram Positive Gram Negative 
MRSA MRSE VREF E. coli P. A. K. P. 
HC50 
(µg/m
L) 
SI 
(MIC/
HC50) 
P1 6.25 3.12 25 6.25 6.25 >50 125 20 
P2 12.5 >50 >50 6.25 12.5 >50 62.5 5 
P3 25 >50 >50 3.12 25 >50 >250 >10 
P4 12.5 >50 >50 25 >50 >50 >250 >20 
Compound P1 was investigated of its ability to disrupt bacteria membranes of MRSA and E. coli. 
Two dyes, 4′,6-diamidino-2-phenylindole (DAPI) and propidium iodide (PI) (Figure 3.2), were used to 
differentiate between cells with either an intact or a damaged membrane. DAPI can permeate the 
membrane of intact cells therefore shows blue fluorescence regardless of cell viability. In contrast, PI 
is a DNA intercalator but lacks cell permeability. It fluoresces in red only when cell membranes are 
disrupted. As shown in Figure 3.2, in the DAPI channel, both MRSA and E. coli exhibited blue 
fluorescence in the absence of compound P1. In the PI channel, neither strain showed red fluorescence 
indicating the membranes of these bacteria were intact. However, after treated with compound P1 for 
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2 h at 2 x MIC, both MRSA and E. coli exhibited red fluorescence, suggesting that the membranes of 
both MRSA and E. coli were disrupted.  
 
Figure 3.2 Fluorescence micrographs of MRSA and E. coli treated or not treated with 2 x MIC of 
compound P1 for 2 h. 
 
To understand the bacteria membrane-disruptive kinetics, time kill assay of compound P1 was 
also carried out. MRSA and E.coli was treated with different concentrations of compound P1: 2× MIC, 
4× MIC and 8× MIC. In Figure 3.3, MRSA can be eliminated within 60 min at all three concentrations. 
Growth of E. coli was effectively controlled and decreased at all three concentrations. This indicates 
that compound P1 can rapidly kill both MRSA and E. coli bacteria strains. 
 
Figure 3.3 Time-kill plot of compound P1 against MRSA and E. coli. 
 
Since compound P1 was designed to be membrane active and disrupt bacterial membranes rather 
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than acting on specific targets, we hypothesized that P1 could also prevent the development of 
resistance in bacteria. Therefore, we carried out drug resistance studies for P1 against E. coli. To do so, 
P1 was incubated with E. coli at half of its MIC overnight, and the new MIC was measured subsequently. 
After 14 passages, the MICs of P1 remained relatively stable (Figure 3.4), which strongly suggests that 
this class of polymyxin mimic cyclic compounds does not readily induce resistance in bacteria, thereby 
suggesting their potential therapeutic potent. 
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Figure 3.4 Drug resistance study for compound P1. 
 
The development of membrane-active antibacterial peptides has been hindered by difficulties 
with systematic toxicity and tissue distribution, thus only a few compounds have been reported with in 
vivo activity and advanced into clinical trials. We envisioned that our polymyxin mimic cyclic peptides 
may possess better therapeutic potential. We employed the thigh burden model to evaluate the in vivo 
anti-infective activity of compounds P1, which is a widely used animal model for evaluating preclinical 
antimicrobial activity of compounds.153 Thigh muscle of neutropenic mice was inoculated with MRSA, 
followed by intravenous (i.v.) injections of the compound P1. As shown in Figure 3.5, significant 
activity was observed at the dose of 5 mg/kg when administered twice with a 6 h and 12 h interval 
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between each injection. A 1-log10 decrease in colony-forming unit (CFU) was observed when injections 
interval is 6 h, while a more significant decrease (4-log10 CFU) was observed when injections interval 
is 12 h. In vivo results suggested that compound P1 provided significant antibiotic activity against 
infection with MRSA. 
 
Figure 3.5 In vivo efficacy of the compounds P1 in the thigh-infection mouse model. 
 
3.3 Conclusions 
In summary, we have developed a new class of polymyxin mimic cyclic peptides which possess 
broad-spectrum antimicrobial activity. These compounds exhibit remarkable potency against a panel 
of multidrug-resistant Gram-positive and Gram-negative bacteria. These compounds were designed to 
be membrane active with both cationic charged and hydrophobic groups. Our studies suggest that the 
lead compound could kill bacteria rapidly and the susceptibility of MRSA remained stable even after 
14 passages. Furthermore, results of MRSA-infected thigh burden mouse model confirmed great 
antibiotic therapeutic potential of the lead compound. Therefore, this class of compounds can be 
potential broad-spectrum antibiotic agents to combat drug resistance. Further studies on the 
optimization of activity and selectivity are currently underway. 
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3.4 Experimental 
3.4.1 General information 
2-Chlorotrityl chloride (CTC) resins (0.972 mmol/g, 100‒200 mesh) were purchased from Chem-
Impex Int’l Inc. Solvents and other chemicals were ordered from either Fisher Scientific or Sigma-
Aldrich, and were used without further purification. The solid phase syntheses of all compounds were 
carried out in a peptide reaction vessel on a Burrell Wrist-Action shaker. All compounds were analyzed 
and purified using the Waters Breeze 2 HPLC system under 215 nm of UV detector equipped with both 
analytical and preparative modules. The desired fractions were lyophilized on a Labcono lyophilizer.  
3.4.2 Synthesis of building block 
 
Figure 3.6 Structures of γ-AApeptide building blocks 
 
Synthesis of γ-AApeptide building blocks is similar as Chapter 2. 
3.4.3 Synthesis of polymyxin mimic peptides 
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Figure 3.7 Synthetic procedure of the compound P1.  
200 mg CTC resin (0.196 mmol) was reacted with Fmoc-Thr(tBu)-OH (0.23 g, 0.588 mmol) and 
DIPEA (50 μL, 0.287 mmol) in DCM solution for 3 h, followed by DMF (2 mL × 3) and DCM (2 mL 
× 3) wash. Then resin beads were capped in methanol for 30 min. The attachment of the Fmoc-
Dab(Boc)-OH to the resin was achieved by adding Fmoc-Dab(Boc)-OH (176 mg, 0.4 mmol), DIC (100 
μL, 0.7 mmol), and HOBt (0.1 g, 0.8 mmol) in 3 mL DMF to the reaction vessel, and the reaction was 
allowed to shake at room temperature for 3 h. Then the solution was drained, and the beads were washed 
with DCM (3 mL × 3) and DMF (3 mL × 3). After that, beads were treated with 3 mL 20% 
piperidine/DMF (v/v) solution for 15 min (× 2) to remove the Fmoc protection group, followed by DMF 
(2 mL × 3) and DCM (2 mL × 3) wash. This step was repeated once, Fmoc-Dab(Boc)-OH was added 
to the resin again . Next, Fmoc-L-leucine (141mg, 0.4 mmol), DIC (100 μL, 0.7 mmol), and HOBt (0.1 
g, 0.8 mmol) in 3 mL DMF were added to the resin and allowed to react for 3 h at room temperature 
after Fmoc protecting group was removed first. This step was repeated once, Fmoc-L-leucine was added 
to the resin again. Next, Fmoc-Dab(Boc)-OH (176 mg, 0.4 mmol), DIC (100 μL, 0.7 mmol), and HOBt 
(0.1 g, 0.8 mmol) in 3 mL DMF was added to the reaction vessel after Fmoc protecting group was 
removed. After beads were washed by DMF and DCM and Fmoc protecting group was removed, Fmoc-
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Dab(Alloc)-OH (170mg, 0.4 mmol), DIC (100 μL, 0.7 mmol), and HOBt (0.1 g, 0.8 mmol) in 3 mL 
DMF was added to the reaction vessel. The solution was drained and beads were washed with DMF 
and DCM. Next, Fmoc-Dab(Boc)-OH (176 mg, 0.4 mmol), DIC (100 μL, 0.7 mmol), and HOBt (0.1 g, 
0.8 mmol) in 3 mL DMF was added to the reaction vessel after Fmoc protecting group was removed. 
After that, Fmoc-Thr(tBu)-OH (0.23 g, 0.588 mmol), DIC (100 μL, 0.7 mmol), and HOBt (0.1 g, 0.8 
mmol) in 3 mL DMF was added to the reaction vessel after Fmoc protecting group was removed. Next, 
Fmoc-Dab(Boc)-OH (176 mg, 0.4 mmol), DIC (100 μL, 0.7 mmol), and HOBt (0.1 g, 0.8 mmol) in 3 
mL DMF was added to the reaction vessel after Fmoc protecting group was removed. Then, palmitic 
acid ( 0.1g, 0.4 mmol) DIC (100 μL, 0.7 mmol), and HOBt (0.1 g, 0.8 mmol) in 3 mL DMF was added 
to the reaction vessel after Fmoc protecting group was removed. Then beads were with Pd(PPh3)4 (24 
mg, 0.02 mmol) and Me2NH.BH3 (70 mg, 1.2 mmol) in 3 mL DCM for 10 min (×2) to remove the alloc 
protein group, then washed with DCM (3 mL x3) and DMF (3 mL ×3).followed by the incubation with 
4 mL cocktail of 1:1:8 TFE: acetic acid: DCM 1:1 (v/v/v) for 2 h to achieve cleavage of the compound. 
After the solvent was removed in vacuo, the residue was reacted with HOBt (73mg, 0.588 mmol), 
TBTU (188mg, 0.588 mmol) and DMAP (120mg, 0.98 mmol) in 500 mL DCM solvent for overnight. 
Then, all remained protecting groups were removed by incubated with 20 mL cocktail of 1:1 TFA: DCM 
1:1 (v/v) for 2 h, after the solution was extracted and solvent was evaporated. Then the compound was 
analyzed and purified on the Waters HPLC system, and the desired fraction was lyophilized to give the 
pure product compound P1. 
Compound P2, P3 and P4 were synthesized with similar methods. 
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Figure 3.8 Structures of compound P1-P4. 
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3.4.4 In vivo study of mouse thigh burden infection model.154 
All protocols and methods associated with animal experiments were approved by University of 
South Florida (USF) Institutional Animal Care and Use Committee. The CD-1 female mice which were 
6 to 8 weeks old and around 25 g in weights were used for the study. Neutropenic Mice were induced 
by injecting cyclophosphamide (150 mg/kg) intraperitoneally twice at 4 and 1 days before bacterial 
inoculation. One MRSA colony from TSA cultures was allowed to grow in TSB medium overnight at 
37 °C, then 100 μL culture was withdrawn and diluted with TSB to a total volume of 4 mL, which was 
subsequently incubated at 37 °C for another 6 h. The bacterial culture was then diluted in sterile 1x PBS 
buffer. The thigh burden infection model was established by injecting both posterior thighs of mice with 
100 μL of inoculums. Two doses of the compounds P1 were given at 1 h/ 7 h and 1 h/ 13 h by i.v. bolus 
injection in the tail vein at 5 mg/kg per dose of drugs after bacterial infection. Thighs were harvested at 
25 h for both groups after bacterial inoculation. Thigh muscles were collected in a sterile tared tube, to 
which 5 mL sterile PBS buffer was added. The mixture was then homogenized with a tissue 
homogenizer (BioSpec product tissue tearor 985-370) for approximately 30 sec. 100 mL of serial diluted 
aliquots were plated on TSA plates, which were incubated for 24 h at 37 °C. Then bacteria colonies 
were counted to calculate CFU per thigh. 
MICs assay, time kill assay, hemolytic assay, drug resistance assay and fluorescence microscopy 
were the same as Chapter 2. 
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CHAPTER 4: SMALL LINEAR MOLECULES AS ANTIBIOTIC AGENTS 
4.1 Introduction 
Due to the omnipresent threat of bacterial infection is still a serious public health concern, AMPs 
have gained considerable interest.155 AMPs perform their function by electrostatic and hydrophobic 
interaction, kill bacteria by damaging their cell membranes.93 However, development of AMPs is 
impeded by their intrinsic drawbacks, such as poor selectivity, susceptibility to proteolytic degradation, 
and low-to-moderate activity. Furthermore, most antimicrobial peptides have large molecular weights 
(>1000 Da), and synthesis is too complex for production. As such, antimicrobial peptidomimetics 
started to draw attentions, which are smaller in size but still retain potential broad-spectrum activity.99 
The new class of peptidomimetics “γ-AApeptide” developed by our group have been shown resistance 
to proteolytic degradation, and various side chain acylating agents can create almost limitless chemical 
diversity.156 These advantages make γ-AApeptide a promising candidate for paralleling function and 
structure of AMPs.157 Indeed, a variety of γ-AApeptides have been developed and displayed potent and 
broad-spectrum antimicrobial activity. However, most lead compounds are long sequences which 
require multi steps synthesis. If small molecules can be developed based on γ-AApeptides, it would 
enhance potential application significantly. Moreover, a few research groups have reported the study of 
peptidomimetic a-hybrid peptidic oligomers for antimicrobial activity, which had unexpected 
antimicrobial activity and low hemolytic activity.158-159 Previously, our group has developed a class of 
lipo-linear α/γ-AApeptides that utilize a hybrid backbone of α-peptide with γ-AApeptides.160 This class 
of peptides display broad-spectrum antimicrobial activity. Therefore, the heterogeneous backbone could 
further enhance the chemodiversity for future optimization and development. 
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4.2 Results and discussion 
From previous studies in Chapter 2, we know that amphipathic property is essential for HDPs. 
Therefore, we designed a series of small linear molecules based on structures. Different hydrophobic 
groups and cationic charged groups were rationally introduced and distributed to find out the best potent 
antimicrobial agent. All small linear molecules were synthesized on solid phase. The synthesis is very 
straightforward (Scheme 4.1), which allowed compounds to be synthesized efficiently.  
 
Figure 4.1 General approach of small linear molecules synthesis on solid phase. 
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Compound R1 R2 R3 CX 
L1  
 
 C5H13 
L2  
 
 C9H19 
L3  
 
 C11H23 
L4  
 
 C13H27 
L5  
 
 C15H31 
L6 
  
 C11H23 
L7  
 
 C11H23 
L8 
 
 
 
C11H23 
L9 H 
 
 C11H23 
L10 
 
 
 C11H23 
Figure 4.2 Structure-based design of compound L1-L23. 
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 C13H27 
L12 
 
 
 C15H31 
L13    
C11H23 
L14    
C11H23 
L15    
C11H23 
L16    C11H23 
L17    
C11H23 
L18    
C11H23 
L19    
C11H23 
L20    
C11H23 
L21  
 
 C15H31 
L22 
   
C15H31 
L23  
 
 
C11H23 
Figure 4.2 Continued Structure-based design of compound L1-L23. 
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Compound R1 R2 R3 R4 Cx 
L24  
 
  C11H23 
L25  
 
 
 
C11H23 
L26  
 
 
 
C15H23 
L27 
  
  C11H23 
L28 
  
 
 
C11H23 
Figure 4.3 Structure-based design of compound L24-L28. 
 
 
Co
mpo
und 
R1 R2 R3 R4 R5 Cx 
L29  
 
   C11
H23 
L30  
 
   C15
H31 
Figure 4.4 Structure-based design of compound L29-L30. 
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und 
R1 R2 R3 R4 R5 Cx 
L31   
 
  C11
H23 
Figure 4.5 Structure-based design of compound L31. 
 
 
Compound R1 R2 R3 R4 Cx 
L32   
 
 C11H23 
Figure 4.6 Structure-based design of compound L32. 
 
 
Compound R1 R2 R3 Cx 
L33 
 
  C11H23 
Figure 4.7 Structure-based design of compound L33. 
 
All small linear molecules were tested against a panel of Gram-positive bacteria for their 
antimicrobial activity (Table 4.1). As shown in Figure 4.2, compounds L1-L23 are composed by 1 
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amino acid, 1 γ-AApeptide building block with urea side chain and Cx lipid tail. Compound L1-L5 
have the same R1, R2 and R3 groups, but the length of Cx group is varied. When compared MICs 
results in Table 4.2, L3 and L4 have better antimicrobial activity than other compounds which indicated 
that C12 and C14 lipid tails lead to the activity increase. Compound L10 has the best overall 
antimicrobial activity among L3, L6, L7, L8, L9 and L10, which have the same R2, R3 and Cx groups 
and varied amino acid at R1 position. Compared to Lys, Arg, Leu, Try and Gly residue, Glu residue has 
the best activity that all MICs are lower than 4 µg/mL. When changing the length of C12 lipid tail on 
L10 to C14 and C16, L11 and L12 have no activity improvement. When compared MICs of compound 
L3 with L13-L20, it is obvious that L3 has the overall best antimicrobial activity. They have the same 
R1, R3 and Cx groups and different R2 groups. It’s indicated that 1-chloro-3-isocyanatobenzene 
provided the best antimicrobial activity among these urea functional groups. MICs of compound L23 
indicates that there is no activity. Therefore, Lys residue on R3 position is essential. As shown in Figure 
4.3, compounds L24-L28 have an extra amino acid compared to compounds in Figure 4.2. When 
compared MICs of L3, L24 and L25, L3 has better activity which indicates that one extra Lys amino 
acid and Phe amino acid could not increase antimicrobial activity of compound. Same results appeared 
when compared L10, L27 and L28. Furthermore, increasing length of C12 lipid tail to C16 decreased 
the activity when comparing MICs of L25 and L26. As shown in Figure 4.4 and 4.5, compound L29-
L31 have one more amino acid compareds with compounds in Figure 4.3. When compared MICs of 
L24 and L29, the increased Lys amino acid didn’t make obvious improvement. The same situation was 
happened when comparing L27, L30 and L31. Furthermore, L32 was designed by adding one Lys 
amino acid to compound L23, still no antimicrobial activity. As shown in Figure 
4.7, compound L33 was designed by switching order of Lys amino acid and γ-Lys-BB of compound L3, 
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which did not increase the antimicrobial activity.  
To summary all MICs results, it is indicated that the number and property of amino acids, length 
of Cx lipid tail and urea side chains are essential to antimicrobial activity and L10 is the lead compound. 
Table 4.1 Antibiotic activity of linear small molecule compounds. 
Compound 
MIC (µg/mL) 
Gram Positive 
MRSA MRSE VREF 
L1 >50 >50 >50 
L2 25 25 >50 
L3 3.12 6.25 6.25 
L4 3.12 6.25 6.25 
L5 3.12 >50 25 
L6 6.25 3.12 >50 
L7 3.12 3.12 >50 
L8 3.12 3.12 >50 
L9 6.25 3.15 6.25 
L10 1.56 3.12 1.56 
L11 3.12 >50 6.25 
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Table 4.1 Continued Antibiotic activity of linear small molecule compounds. 
L12 25 >50 >50 
L13 12.5 12.5 25 
L14 25 25 >50 
L15 >50 >50 >50 
L16 >50 >50 >50 
L17 6.25 6.25 >50 
L18 6.25 3.12 >50 
L19 12.5 6.25 >50 
L20 >50 >50 >50 
L21 6.25 6.25 >50 
L22 1.56 1.56 12.5 
L23 >50 >50 >50 
L24 12.5 25 >50 
L25 3.12 3.12 >50 
L26 >50 >50 >50 
L27 6.25 3.12 >50 
L28 >50 >50 >50 
L29 6.25 3.12 >50 
L30 3.12 6.25 >50 
L31 6.25 3.12 >50 
L32 >50 >50 >50 
L33 3.12 12.5 >50 
 
To study the selectivity of small linear molecules, hemolytic assay was carried out. As shown in 
Table 4.2, compound L10 not only has the best antimicrobial activity but also has the best selectivity 
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over MRSA among this series of small linear compounds. 
Table 4.2 Selectivity of linear small molecule compounds.  
Compound 
MIC of MRSA 
(µg/mL) 
HC50 (µg/mL) SI (MIC/HC50) 
L2 25 125 5 
L3 3.12 62.5 20 
L4 3.12 31.25 10 
L5 3.12 31.25 10 
L6 6.25 31.25 5 
L7 3.12 45 14.4 
L8 3.12 31.25 10 
L9 6.25 125 20 
L10 1.56 62.5 40 
L11 3.12 125 40 
L12 25 125 5 
L13 12.5 125 10 
L14 25 125 5 
L17 6.25 62 10 
L18 6.25 45 7 
L19 12.5 250 16 
L21 6.25 31.25 5 
L22 1.56 15 10 
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Table 4.2 Continued Selectivity of linear small molecule compounds.  
L25 1.56 30 19.2 
L27 6.25 31.25 5 
L29 6.25 80 12.8 
L30 3.12 31.25 10 
L31 6.25 150 24 
L32 >50 62.5 <1.25 
L33 3.12 80 25.6 
 
We next conducted time-kill studies of compound L10 to study its bacteria killing kinetics. As 
shown in Figure 4.8, MRSA was treated with compound L10 at three different concentrations: 2× MIC, 
4× MIC, and 8× MIC. Treatment L10 at 2× MIC, 4× MIC can control and slow down MRSA growing. 
Furthermore, at 8× MIC, compound L10 can eradicate MRSA completely within 30 min. This indicate 
that L10 can kill MRSA rapidly. 
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Figure 4.8 Time-kill plots of L10 against MRSA. 
Next, their impact on bacterial membranes was tested by fluorescent microscopic studies. 
Compound L10 was tested against MRSA at 2× MIC for 2 h. As shown in Figure 4.9, in the DAPI 
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channel, MRSA cells emitted blue fluorescence with and without L10 treatment. However, MRSA cells 
only emitted red fluorescence with L10 treatment, indicating that their membranes were disrupted 
therefore stained by PI dye. 
 DAPI PI 
MRSA 
  
MRSA 
+ 
P10 
  
Figure 4.9 Fluorescence micrographs of MRSA treated and not treated with 2XMIC. 
(a1) Control, no treatment, DAPI stained; (a2) control, no treatment, PI stained; (b1) MRSA treated 
with L10, DAPI stained; (b2) MRSA treated with L10, PI stained. 
 
4.3 Conclusions 
In summary, we investigated a new class of small linear molecules as potential antibiotic agents 
against Gram-positive bacteria. They were structure-based designed with both cationic charged groups 
and hydrophobic groups. Our studies suggest that these compounds can disrupt bacteria membranes and 
kill bacteria rapidly. Due to their small molecular weight and facile synthesis approach, they could be 
potential antibiotic agents. Further characterization of lead compound are currently underway in our lab.  
4.4 Experimental 
4.4.1 General information 
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Rink amide MBHA resins (0.7 mmol/g, 200‒400 mesh) were purchased from Chem-Impex Int’l 
Inc. The solid phase syntheses of all compounds were carried out in a peptide reaction vessel on a 
Burrell Wrist-Action shaker. Solvents and other chemicals were ordered from either Fisher Scientific 
or Sigma-Aldrich, and were used without further purification. All compounds were analyzed and 
purified using the Waters Breeze 2 HPLC system under 215 nm of UV detector equipped with both 
analytical and preparative modules. The desired fractions were lyophilized on a Labcono lyophilizer.  
4.4.2 Synthesis of γ-AApeptide building blocks 
 
Figure 4.10 γ-AApeptide building blocks. 
 
Method to synthesize γ-AApeptides building blocks is the same as Chapter 2. 
4.4.3 Synthesis of small linear compounds on solid phase 
 
Figure 4.11 Synthesis of compound L10. 
 
Synthetic procedure of the compound L10: 200 mg Rink-amide (MBHA) resin (0.14 mmol) was 
treated with 3 mL 20% piperidine/DMF (v/v) solution for 15 min (× 2) to remove the Fmoc protection 
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group, followed by DMF (2 mL × 3) and DCM (2 mL × 3) wash. The attachment of Fmoc-L-
Phenylalanine to the resin was achieved by adding Fmoc-L-Phenylalanine (155 mg, 0.4 mmol), DIC 
(101 mg, 114 μL, 0.8 mmol), and HOBt (122 mg, 0.8 mmol) in 3 mL DMF to the reaction vessel, and 
the reaction was allowed to shake at room temperature for 3 h. The solution was drained, and the beads 
were washed with DCM (3 mL × 3) and DMF (3 mL × 3). After that, beads were treated with 3 mL 20% 
piperidine/DMF (v/v) solution for 15 min (× 2) to remove the Fmoc protection group, followed by DMF 
(2 mL × 3) and DCM (2 mL × 3) wash. Then add γ-Lys-BB (238 mg, 0.4 mmol), DIC (101 mg, 114 μL, 
0.8 mmol), and HOBt (122 mg, 0.8 mmol) in 3 mL DMF to the reaction vessel, and the reaction was 
allowed to shake at room temperature for 3 h. The solution was drained, and the beads were washed 
with DCM (3 mL × 3) and DMF (3 mL × 3). After that, the resin was treated with Pd(PPh3)4 (24 mg, 
0.02 mmol) and Me2NH.BH3 (70 mg, 1.2 mmol) in 3 mL DCM for 10 min (×2) to remove the alloc 
protein group, then washed with DCM (3 mL x3) and DMF (3 mL ×3). Next, 3-chlorophenyl isocyanate 
(77 mg, 61 μL, 0.5 mmol) and DIPEA (65 mg, 87 μL, 0.5 mmol) in 3 mL DCM were added to the resin 
and allowed to react for 30 min at room temperature, and then the solution was drained. After DMF (2 
mL ×3) and DCM (2 mL ×3) wash, beads were treated with 3 mL 20% piperidine/DMF (v/v) solution 
for 15 min (× 2) to remove the Fmoc protection group, followed by wash with DMF (2 mL ×3) and 
DCM (2 mL ×3). Subsequently, lauric acid (80 mg, 0.4 mmol), DIC (101 mg, 114 μL, 0.8 mmol), and 
HOBt (122 mg, 0.8 mmol) in 3 mL DMF were added to the reaction vessel and reacted for 3 h. After 
the solution was drained, the beads were washed with DMF (2 mL ×3) and DCM (2 mL ×3), followed 
by the incubation with 4 mL cocktail of 1:1 TFA: DCM 1:1 (v/v) for 2 h to achieve cleavage and global 
deprotection of the compound. After the solvent was removed in vacuo, the residue was analyzed and 
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purified on the Waters HPLC system, and the desired fraction was lyophilized to give the pure product 
L10. 
Synthesis of other compounds: The other compounds were synthesized following the similar 
procedure of compound L10. 
 
 
 
  
 
Figure 4.12 Structures of small linear compounds L1-L33. 
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Figure 4.12 Continued Structures of small linear compounds L1-L33. 
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Figure 4.12 Continued Structures of small linear compounds L1-L33. 
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Figure 4.12 Continued Structures of small linear compounds L1-L33. 
MICs assay, time kill assay, hemolytic assay and fluorescence microscopy were the same as 
Chapter 2. 
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CHAPTER 5: ONE-BEAD−TWO-COMPOUND THIOETHER BRIDGED MACROCYCLIC 
γ‑AA PEPTIDES SCREENING LIBRARY AGAINST SMYD2 
5.1 Introduction 
During this new era of development and discovery of numerous new disease targets, 
combinatorial chemistry is a powerful tool to identify ligands that recognize protein targets with high 
specificity and affinity, therefore could help to understand and diagnose function of proteins and lead 
to potential therapeutic treatment.57 Combinatorial library can synthesize large number of possible 
compounds and provide unbiased opportunity for ligand identification. In 1990s, combinatorial library 
methods became key technology for accelerating the discovery of novel therapeutic agents and had 
various applications in many fields, such as peptides,40-41 oligonucleotides,42-43 proteins,44 synthetic 
oligomers,45 small molecules,46 and oligosaccharides.47 However, only a few of peptidomimetic 
combinatorial libraries were investigated for protein ligand identification. 
According to our previous study, γ-AApeptides have high resistance to proteolytic degradation 
and enhanced chemodiversity, which make them ideal candidates for molecular probes and therapeutic 
agents. These advantages of γ-AApeptides have been demonstrated by our previously developed one-
bead-one-compound (OBOC) linear combinatorial libraries, which capable of finding hits to inhibit Aβ 
aggregation and disrupt STAT3/DNA interaction.37-38 Compared to linear γ-Aapeptides, cyclic γ-
AApeptides are more stable against proteolytic degradation and possess cellular translocation 
capability.161 Thus, we developed a one-bead-two-compound (OBTC) cyclic γ-AApeptides-based (γ-
substituted-N-acylated-N-aminoethyl amino acids) combinatorial library against SMYD2. 
SET and MYND domain-containing protein 2 (SMYD2) is a lysine methyltransferase that is 
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highly expressed in pediatric acute lymphoblastic leukemia and esophageal squamous cell carcinom.162-
163 Its function as a methyltransferase has been reported to various substrates including retinoblastoma 
tumor suppressor (Rb) (K860),164 histone H3 (K36 and K4),165-166 and tumor suppressor p53 (K370).167-
168 SMYD2 is believed to play an important role in the network of post-translational modifications that 
regulates tumor growth. Therefore, finding hits binding to SMYD2 protein is essential for potential 
cancer treatment. 
5.2 Results and discussion 
One-bead-two compound cyclic γ-AApeptides-based library was synthesized on Tenta-Gel due 
to it is non-sticky and uniform in size. Cyclic peptides were achieved by thioether-bridge mediated 
cyclization, which has proven to be highly efficient in cyclization. Compared with linear peptides, 
cyclic peptides have rigidified conformational freedom and enhanced metabolic stability. Heinis et al 
also adopted the thioether linkage to develop phage-display mediated bicyclic peptide libraries.169-171 
As shown in Figure 5.1 we introduced a Dmt (4,4′-dimethoxytrityl) protected mercaptoethyl carbonyl 
group to the secondary amine in the first γ-AApeptide building block on the solid phase. The 4-
(bromomethyl)benzoyl group was attached to the N-terminal amino group of the sequence after all γ-
AApeptide building blocks were added. After that, Dmt protecting group was removed and cyclization 
was achieved with high efficiency of sulfur-mediated SN2 reaction (Figure 5.2). 
 
Figure 5.1 Structure design of one-bead-two compound cyclic γ-AApeptides-based library. 
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Figure 5.2 Reaction of thioether-bridge cyclization.  
 
As shown in Figure 5.1, five different N-Alloc protected γ-AApeptide building blocks were added 
to position X1-X4 and six diverse carboxylic acids or acyl chlorides side chains were added to position 
Y2-Y4 after deprotection of the alloc protecting group. Therefore, the theoretical diversity of the library 
was expected to be 5x5x6x5x6x5x6=135000, and 405000 beads were used in library synthesis with 
each compound has three copies. 
Dde ((1-(4,4-dimethyl-2,6-dioxacyclohexylidene) ethyl) protected α-amino acids were used to 
encode and decode structures of compound because that deprotection of Dde was very mild using 
NH2OH•HCl and imidazole and had no effect on other chemical reactions engaged in the synthesis of 
thioether-bridged cyclic γ-AApeptides.172 In Figure 5.2, corresponding Dde protected amino acid were 
added to position R1-R7. 
Library screening was carried out after library synthesis was complete. To conduct screening, 
Tenta-Gel beads were incubated with SMYD2 protein first and then primary and secondary SMYD2 
antibody. Beads emitting fluorescence were picked as hits (Figure 5.3). 
  
Figure 5.3 Screening of the one-bead-two compound cyclic γ-AApeptides-based library. 
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Subsequently, hits were washed, denatured carefully and cleaved with CNBr. After MS/MS 
analysis, structures of hits were decoded and hits were resynthesized on rink amide resin. Among 10 
hits, three hits were decoded and resynthesized (Figure 5.4). 
 
 
 
Figure 5.4 Structures of three hits. 
Further bioactivity tests are underway. 
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5.3 Experimental 
5.3.1 General information  
Rink amide MBHA resins (0.7 mmol/g, 200‒400 mesh) were purchased from Chem-Impex Int’l 
Inc. TentaGel resin (0.23 mmol/g) was purchased from RAPP Polymere.Solvents and other chemicals 
were ordered from either Fisher Scientific or Sigma-Aldrich. Fmoc-protected amino acids were 
purchased from Chem-impex. The solid phase syntheses of all compounds were carried out in a peptide 
reaction vessel on a Burrell Wrist-Action shaker. All compounds were analyzed and purified using the 
Waters Breeze 2 HPLC system under 215 nm of UV detector equipped with both analytical and 
preparative modules. The desired fractions were lyophilized on a Labcono lyophilizer. Masses of γ-
AApeptides and the MS/MS analysis were obtained on an Applied Biosystems 4700 Proteomics 
Analyzer. 
5.3.2 Synthesis of γ-AApeptide building blocks 
 
Figure 5.5. γ-AApeptide building blocks. 
 
All 5 γ-AApeptide building blocks shown above were used in the synthesis of One-bead Two-
compound library; their synthetic procedure was reported previously.126 
72 
 
5.3.3 Synthesis of Dde protected amino acids 
 
Figure 5.6 Synthesis of Dde protected amino acids 
 
Figure 5.7 Structures of all Dde protected amino acids. 
To a 100 mL round bottom flask was added 5,5-dimethylcyclohexane-1,3-dione (10 g, 71.34 
mmol), N, N-Diisopropylethylamine (14.91mL, 85.6 mmol), 4-Dimethylaminopyridine (435.76mg, 
3.57 mmol) and 50 mL DCM. The mixture was stirred in an ice bath to which acetyl chloride (6.08 mL, 
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85.6 mmol) was added. The reaction was warmed up to room temperature and allowed to stir for 8 h. 
After solvent was removed and the residue was washed with 1M HCl and extracted with ethyl acetate 
for 3 times. The organic layer was dried with anhydrous Na2SO4, then was purified by flash column 
chromatography (Hexane/Ethyl acetate 1:1). The product 2-acetyl-5,5-dimethylcyclohexane-1,3-dione 
is a yellowish solid 
The L-Amino acid (1 equiv), 2-acetyl-5,5-dimethylcyclohexane-1,3-dione (1.3 equiv) and 
triethylamine (1.5 equiv) was refluxed in 50mL ethanol for 18 h. The reacted yellow solution then was 
cooled and concentrated. The residue was dissolved in 50 mL DCM, and washed with 50 mL 1 M HCl 
twice. The organic layer was dried by Na2SO4 and filtered. After solvent DCM was removed, add 40mL 
Et2O to the residue resulted in immediate white precipitate, which was filtered and washed with cold 
Et2O to abtain off-white crystalline solid as product. 
5.3.4 Synthesis of side chains and linkers 
 
Figure 5.8 Structures and synthesis of 6 side chains. 
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Side chain 3 cyclopropylacetic acid was purchased from AK Scientific. Side chain 6 3,4-
(methylenedioxy) phenylacetic acid was purchased from TCI. 
Synthesis of side chain 1: the 3-Cyclohexanepropionic acid was refluxed in 10 mL thionyl 
chloride for 5 h. The excess thionyl chloride was removed under vacuum. The desired product is a white 
solid and can be used without purification. 
Synthesis of side chain 2: same as side chain 1. 
Synthesis of side chain 4: 4-Aminobutyric acid (5g, 40.5 mmol) was dissolved in 150 mL THF 
at 0 degree Celsius. Di-tert-butyl decarbonate (14 mL, 60.9 mmol) and 1M NaOH (49 mL) were then 
added to solution. The mixed was stirred at room temperature for 3 h. Remove the solvent and add water 
(30 mL) and ethyl acetate (20 mL). Adjust PH of solution to 2 by adding 1M HCl. The solution was 
exact with ethyl acetate three times, and organic layer was dried with anhydrous sodium sulfate. After 
flash column purification, the desired product is a white solid.  
Synthesis of side chain 5: to a mixture of succinic anhydride (30g, 0.3 mol), N-
hydroxysuccinimide (10g, 0.09 mol) and DMAP (3.5g, 0.03 mol) in toluene (150 mL), add tert-butyl 
alcohol (35mL) and Et3N (12.5mL, 0.09 mol). The mixture was refluxed for 24 h. Then cool the solution 
and add 150 ethyl acetate (150mL). Wash solution with 10% citric acid and dried with anhydrous 
sodium sulfate. The solvent was removed and residue was recrystallize by ether and petroleum ether at 
-20 degree Celsius. The desired product is a white solid.   
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Figure 5.9 Structures and synthesis of 2 linkers. 
 
Synthesis of linker 1: the 4-(bromomethyl) benzoic acid was refluxed in 10 mL thionyl chloride 
for 5 h. The excess thionyl chloride was removed under vacuum. The desired product is a white solid 
and can be used without purification. 
Synthesis of linker 2: 4,4'-dimethoxytrityl chloride (6.38g, 18.82 mmol), 3-mercaptopropionic 
acid (1.64ml, 18.82 mmol) and triethylamine (3.93, 22.58 mmol) were dissolved in 40 mL DCM. The 
solution was stirred at room temperature for 4 h~ 6 h. After evaporated solvent, the residue was washed 
with saturated citric acid and extracted with ethyl acetate 3 times. Organic layer was dried with 
anhydrous Na2SO4 and the solvent was removed. After purified by flash column chromatography 
(Hexane/Ethyl acetate 1:1), desired product is a light yellow solid 
5.3.5 Synthesis of One-bead Two-compound library 
The One-bead Two-compound cyclic γ-AApeptide library was prepared on solid phase using 
TentaGel NH2 resin (2.64g, 0.61mmol, 405000 beads). Fmoc protecting group was removed by 20% 
(v/v) piperidine in DMF (10 min × 2). Alloc protecting group was removed by Pd(PPh3)4 (8 mg, 0.007 
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mmol) and Me2NH·BH3 (25 mg, 0.42 mmol) in 3 mL DCM (10 min × 2). All γ-AApeptide building 
blocks (2 equiv) and carboxylic acids (2 equiv) were coupled twice to desired amino groups using 
HOBt(4 equiv.) and DIC (4 equiv.) in DMF, each time is 6 h. All the acyl chlorides (2 equiv.) side 
chains were coupled to desired amino groups using DIPEA (4 equiv.) in DCM twice, each time is 30 
min. All Dde protected amino acids (5.5 equiv.) were coupled to the desired amino groups with PyBop 
(5 equiv.) and NEM (11 equiv.) in DMF for 3 h. Dde protecting groups were removed by shaking in 5 
mL Dde deprotection solution and 1 mL DCM twice, each time is 3 h. Dde deprotection solution was 
prepared by NH2OH·HCl (1.25 g, 0.180 mmol) and imidazole (0.918 g, 0.135 mmol) dissolved in 5 mL 
NMP. 
Briefly, TentaGel resin beads was soaked in water overnight to allow two layers separated from 
each other. Inner layer contains a coding peptide and outer layer composes of the cyclic γ-AApeptide 
ligand.Transfer beads into reaction vessel, then rinse the resin three times with 1:1 (v/v) DCM/diethyl 
ether. Add (Boc)2O (0.5 equiv.) and 1:1 (v/v) DCM/diethyl ether to the vessel, then the mixture was 
shaken for 3 h. After reaction is complete, wash beads three times with DCM and DMF. Next, Fmoc-
Met-OH (0.5 equiv.), HOBt (2 equiv.) and DIC (2 equiv.) were added to react with the inner layer of 
the resin. Remove Fmoc protecting group and split beads into 5 equal portions. To 5 reacting vessels, 
add Dde-Ala-OH, Dde-Phe-OH, Dde-Leu-OH, Dde-Val-OH, and Dde-Glu(OBn)-OH, respectively. 
Boc protecting group on the outer layer was removed by using mixture of 94% TFA, 2% TIS 
(triisopropylsilane), 2% H2O and 2% Thioanisole for 1 h, and corresponding γ-AApeptide building 
blocks were coupled on the beads. Next, Alloc protecting group of the first γ-AApeptide building block 
was removed, and Dmt protected mercaptopropionic acid was added. After washed with DMF and 
DCM, all beads were pooled together and shaken to be mixed thoroughly. Next, split beads into 5 equal 
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portions again. Dde protecting group of the coding peptides on the inner layer was removed and 5 
different Dde protected amino acids were coupled separately in each vessel. Then Fmoc protecting 
group of the first γ-AApeptides on the outer layer was removed and desired γ-AApeptide building 
blocks were added. The beads were pooled and split again, and the synthetic cycle was repeated three 
more times. Then Fmoc group of the outer layer was removed, then beads were reacted with the 4-
(bromomethyl)benzoyl chloride. Next, Dmt protecting group was removed by mixture of 2% TFA, 2% 
triisopropylsilane and 96% DCM for several times until the deprotecting solution became colorless, 
each time is 2 min. The cyclization of γ-AApeptide was achieved with shaking beads in solution of 
(NH4)2CO3 (10 equiv) in 1:1 (v/v) DMF/H2O for 8 h, repeat twice. Wash beads with DMF and DCM. 
Finally, protecting groups on the sidechains were removed with 94% TFA, 2% triisopropylsilane, 2% 
H2O and 2% Thioanisole for 1 h.  
 
 
Figure 5.10 Preparation of the thioether bridged cyclic library.173 (Adapted with permission from 
ACS. Copyright 2017) 
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Figure 5.10 Continued Preparation of the thioether bridged cyclic library.173 (Adapted with 
permission from ACS. Copyright 2017) 
5.3.6 Library screening 
The SMYD2 protein was used as a target for the combinatorial library screening. The beads were 
screened and picked up under a Zeiss inverted fluorescence microscope installed with a 10x43HE filter. 
To avoid any possible nonspecific binding, SMYD2 and antibodies solution were all made in 1% 
BSA/TBST blocking buffer. 
The TentaGel beads (2.64 g, 405000 beads) were soaked in DMF for 1 h. After being washed 
with 1×Tris buffer for five times, the beads were equilibrated in Tris buffer overnight at room 
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temperature. Then beads were incubated with blocking buffer (1% BSA in 1×Tris buffer with a 1000× 
excess of cleared E. coli lysate) for 1 h.  
E. coli lysate preparation: take two colony of E. coli and add to 25 ml TSB media, incubate for 
16 h on the shaker, 250RPM. Then spin down E. coli solution in centrifuge machine (4 °C, 3000RPM, 
15 min), and discard the supernatant liquid (wipe the wall with paper towel to fully remove the liquid). 
Put the solution on EtOH/Dry ice bath. Add 8 ml lysate buffer, re-suspend, combine solution in one 
centrifuge tube rest on ice for 30min. The solution was sonicated while cooling (10 times, each time 10 
sec, rest on ice for 5 sec in between). Next, solution was centrifuged twice (6000rpm, 4 °C), each time 
is 15 min. 
Prescreening: Beads were incubated with primary SMYD2 antibody (1:1000 dilution) for 2h at 
room temperature. After a thorough wash with 1× Tris buffer, the beads were then incubated with the 
secondary SMYD2 antibody(1:1000 dilution) for 2 h at room temperature. The beads were washed with 
1× Tris buffer (3×), and then transferred into a 6-well plate to be observed under Zeiss inverted 
fluorescence microscope installed with the 10×43HE filter. Beads emitting red fluorescence were 
picked up and excluded from formal screening.  
The rest of the beads were pooled together into the peptide vessel, washed with 1× Tris buffer, 
and then treated with 8 M guandine∙HCl at room temperature for 1h to remove any bound proteins. The 
guandine∙HCl was then washed away with both water and Tris buffer. The beads were then shaken in 
DMF for 1 h, followed by washing and equilibration in Tris buffer overnight. 
Screening: The beads were incubated in 1% BSA/Tris buffer and 1000× excess of E. coli lysate 
for 1 h at room temperature. After wash with Tris buffer for 5 times, the beads were incubated with 
SMYD2 protein at a concentration of 50 nM for 4 h at room temperature with E. coli lysate. Next, the 
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library beads were incubated with 10 μL primary SMYD2 antibody in 10 mL solution for 2 h at room 
temperature. The beads were washed by Tris buffer and incubated with 10 μL secondary SMYD2 
antibody for 2 h at room temperature. Beads were washed thoroughly with Tris buffer and then 
transferred into the 6-well plate. Under fluorescence microscope, beads emitting read fluorescence were 
picked up as hits. Each hit bead was transferred to an Eppendorf microtube, and denatured in 100 µL 
8M guanidine•HCl for 1h at room temperature, respectively. Each bead was rinsed with Tris buffer, 
water, DMF, and ACN, each time is 10 min. At last, beads were soaked in ACN overnight in each 
Eppendorf microtube and then ACN was evaporated. The bead was incubated in mixture of 5:4:1 (v/v/v) 
ACN: glacial acetic acid: H2O and cyanogen bromide (50 mg/mL) overnight at room temperature. The 
solution was then evaporated, and cleaved peptide was dissolved in ACN : H2O (4:1) and run MALDI 
MS/MS analysis. 
5.3.7 Synthesis of Hits   
Synthesis of Hit 1: 200 mg Rink-amide (MBHA) resin (0.14 mmol) was treated with 3 mL 20% 
piperidine/DMF (v/v) solution for 15 min (× 2) to remove the Fmoc protection group, followed by DMF 
(2 mL × 3) and DCM (2 mL × 3) wash. Then the first γ-AApeptide building block γ-Ala-BB (176 mg, 
0.4 mmol), DIC (101 mg, 114 μL, 0.8 mmol), and HOBt (122 mg, 0.8 mmol) in 3 mL DMF to the 
reaction vessel, and the reaction was allowed to shake at room temperature for 3 h. The solution was 
drained, and the beads were washed with DCM (3 mL × 3) and DMF (3 mL × 3). After that, beads were 
treated with Pd(PPh3)4 (24 mg, 0.02 mmol) and Me2NH.BH3 (70 mg, 1.2 mmol) in 3 mL DCM for 10 
min (×2) to remove the alloc protein group, then washed with DCM (3 mL x3) and DMF (3 mL ×3). 
Next, Dmt protected mercaptopropionic acid (166 mg, 0.5 mmol) and DIPEA (87 μL, 0.5 mmol) in 3 
mL DCM were added to the resin and allowed to react for 30 min at room temperature, and then the 
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solution was drained. After DMF (2 mL ×3) and DCM (2 mL ×3) wash, beads were treated with 3 mL 
20% piperidine/DMF (v/v) solution for 15 min (× 2) to remove the Fmoc protection group, followed by 
wash with DMF (2 mL ×3) and DCM (2 mL ×3). Then the second γ-AApeptide building block γ-Ala-
BB (176 mg, 0.4 mmol), DIC (101 mg, 114 μL, 0.8 mmol), and HOBt (122 mg, 0.8 mmol) in 3 mL 
DMF to the reaction vessel, and the reaction was allowed to shake at room temperature for 3 h. The 
solution was drained, and the beads were washed with DCM (3 mL × 3) and DMF (3 mL × 3). After 
that, beads were treated with Pd(PPh3)4 (24 mg, 0.02 mmol) and Me2NH.BH3 (70 mg, 1.2 mmol) in 3 
mL DCM for 10 min (×2) to remove the alloc protein group, then washed with DCM and DMF. 
Subsequently, cyclopropylacetic acid (40 mg, 0.4 mmol), DIC (101 mg, 114 μL, 0.8 mmol), and HOBt 
(122 mg, 0.8 mmol) in 3 mL DMF were added to the reaction vessel and reacted for 3 h. After the 
solution was drained, the beads were washed with DMF and DCM, Fmoc protecting group was removed 
and the third γ-AApeptide building block Ala-BB was added. Next, Alloc protecting group was removed 
and 3-phenylpropanoyl chloride (84 mg, 0.5 mmol) and DIPEA (65 mg, 87 μL, 0.5 mmol) in 3 mL 
DCM were added to the resin and allowed to react for 30 min at room temperature. After that, the fourth 
γ-AApeptide building block Phe-BB was added after Fmoc protecting group was removed. Next, 
remove Alloc protecting group and add 3-cyclohexylpropanoyl chloride (87 mg, 0.5 mmol) and DIPEA 
(65 mg, 87 μL, 0.5 mmol) in 3 mL DCM to react for 30 min. Then remove Fmoc protecting group and 
add 4-(bromomethyl)benzoyl chloride (117 mg, 0.5 mmol) and DIPEA (65 mg, 87 μL, 0.5 mmol) in 3 
mL DCM to react for 30 min. Next, Dmt protecting group was removed by treated resin beads with 
mixture of 2% TFA, 2% triisopropylsilane and 96% DCM for several times until the deprotecting 
solution became colorless, each time is 2 min. 
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Then cyclization was achieved with shaking beads in solution of (NH4)2CO3 (10 equiv) in 1:1 (v/v) 
DMF/H2O for 8 h, repeat twice. Wash beads with DMF and DCM. Finally, resin beads was incubated 
with 4 mL cocktail of 1:1 TFA: DCM 1:1 (v/v) for 2 h to achieve cleavage and global deprotection of 
the compound. After the solvent was removed in vacuo, the residue was analyzed and purified on the 
Waters HPLC system, and the desired fraction was lyophilized to give the pure compound Hit 1. 
Synthesis of other 2 Hits is similar as Hit 1. 
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APPENDIX A: 1H AND 13C NMR SPECTRA 
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APPENDIX B: HPLC SPECTRA 
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